Oral single-active-ingredient pantothenic acid (vitamin B5) supplementation × Reduction in inflammatory lesion counts in adults with mild-to-moderate facial acne

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Met	Full text not readStored summary read	N01 · Separate claimWhich single question is linked to the original verdict URL?Required	The current /ko/effect is a reduction in inflammatory lesion counts in adults with mild-to-moderate facial acne. subclaims is an empty array, and the related 028 is linked as a historical mixed claim. This table covers the original main question alone. S01 S03 S04	The current claim, subclaim structure, and original verdict identity were linked to the actual preserved archived summaries. This is separate from verification of efficacy.	The current assessment target, facets, empty subclaims, canonical URL, and identity of the related 028.	Before incorporating new material, use an inclusion/exclusion table to compare the assessment target with the population, intervention, and endpoint of each result.
2	Unverified	Full text not readStored summary read	N02 · Sole active ingredientWas the effect of pantothenic acid alone distinguished from the product effect?Required	The question concerns oral pantothenic acid as the sole active ingredient. The current manuscript could not verify that the 2014 Pantothen product had a sole active ingredient, and keeps calcium pantothenate in a separate verification stratum. Topical, intramuscular, and NAD mechanism material is not used as evidence of the effect of oral monotherapy. S01 S03 S04 S06 S10 S11	The question boundaries are clear, but the actual identity of the directly eligible single-active-ingredient intervention has not been verified.	Material documenting all active ingredients, the exact salt, actual route, product, and batch of the single-active-ingredient formulation.	Code each trial's intervention in a table of ingredients, salts, routes, and concurrent ingredients, and first assess direct comparability.
3	Met	Full text not readStored summary read	N03 · Level of readingWas summary reading in this review distinguished from historical access to original texts?Required	The currently preserved KO/EN text, evidence, and bibliography were actually read. The historical full_text for S01/S04/S06, the full-document PDF for S02, full_text_mirror for S03, metadata_search_index for S05, and inherited_local_record for S09–S11 are preserved unchanged. Access to all external original texts was not attempted, and none were acquired or read in this review. S01 S02 S03 S04 S05 S06 S09 S10 S11	Current summary reading and the historical access level of each material were recorded separately. This does not mean that external full-text verification is complete.	The preserved URL, location, and access_level for each citation, and any records of individual access dates/acquired copies, if available.	For each actual acquisition event, record document type, bytes, verification location, and access/reading times separately, and compare them with the summary reader.
4	Partly verified	Full text not readStored summary read	N04 · Report and trial familiesWere the Yang main text and supplementary slide kept from being double-counted as trials?Required	The S01 main text and S02 single-page summary slide belong to the same Yang 2014 material set. The original evidence labels them S01 F01, S03 F02, S04 F03, and S05 F04. These labels are not newly added up as unique eligible trials, independent replications, or a participant total. S01 S02 S03 S04 S05	The linkage between the same paper and its appendix is verified, but the independent identities and duplication of all studies have not been exhaustively verified.	Each report's DOI, year, trial identity, supplementary-material linkage, and original evidence family_id.	Group related reports in a trial-identity table and compare titles, DOI, duration, populations, and batches to identify duplication and unestablished matters.
5	Unverified	Full text not readStored summary read	N05 · Population and selectionDoes the material directly match adults with mild-to-moderate facial acne?Required	The original target population is adults with mild-to-moderate facial acne. Yang/Capodice are related facial-acne studies, but sole-active-ingredient product status and actual population details have not been established as currently directly eligible evidence. S01 S03	The current facets define the target population for the question, but information on selection and representativeness of an eligible single-active-ingredient population is unverified.	Tables of diagnosis, age/severity distributions, inclusion/exclusion, and baseline treatment in single-active-ingredient trials.	Prepare an eligibility table by diagnosis, severity, and baseline treatment to review differences between the original target population and study populations.
6	Unverified	Full text not readStored summary read	N06 · Deficiency boundaryWas the hypothesis of deficiency correction distinguished from efficacy for acne in general?Supplementary; required for extension to deficiency	The original facets explicitly distinguish this from efficacy in correcting deficiency. Leung 1995 is a bibliographic lead for a deficiency hypothesis and related reports; directly eligible between-group results for inflammatory lesions are unverified. S05	The deficiency boundary was preserved, but the actual population's baseline status or effects by deficiency status have not been verified.	Baseline nutritional status, methods of identifying deficiency, and direct comparative results within that stratum.	Separate deficient and nondeficient strata only in studies with baseline-status data, and compare whether effect modification was prespecified.
7	Unverified	Full text not readStored summary read	N07 · Salt, batch, and qualityWere the salt, formulation, and manufacturing batch of the eligible single-active-ingredient product verified?Required	The manufacturing source, exact salt, brand, purity, batch, release formulation, and medication adherence for the current single-active-ingredient product are unverified. Calcium pantothenate was retained as a separate search stratum, and equal effects with the free acid were not assumed. S01 S03 S06	The formulation identity left unverified in the manuscript cannot be filled in as actual manufacturing certification.	Trial-batch manufacturing/composition certificates, complete label, salt and labeled-amount basis, and formulation-quality data.	Separate the salt, active-amount basis, excipients, and purity in batch records, and compare the trial intervention with the label for agreement.
8	Unverified	Full text not readStored summary read	N08 · 2014 product compositionCan the sole-active-ingredient status of the 2014 Pantothen product be verified?Required	Yang 2014 is a 12-week study of Pantothen. There is a report that 4 tablets contain pantothenic acid 2.2 g, but the complete active composition, exact salt, and trial-batch certificate are currently unverified. An identical batch to the same brand's 2012 composition was not assumed. S01 S02 S03	The amount of pantothenic acid contained and verification that it is the sole active ingredient are different conditions, and the latter is not met.	The complete active composition, exact salt, and batch certificate for the 2014 batch, and comparator ingredients.	Compare the 2014 batch composition with a placebo under the same background treatment, and review whether a comparison isolates the single ingredient.
9	Partly verified	Full text not readStored summary read	N09 · 2012 combination productWere the other ingredients and dosing of the 2012 product distinguished?Required (attribution of related material)	The 2012 Pantothen product is described as having multiple ingredients, including other vitamins and L-carnitine. The dosing was 2 tablets per administration, 2 times daily for 8 weeks, and the manuscript reports that the complete composition extraction and unverified units were left in a separate ledger. That ledger was not read in this review. S03	The preserved description of multiple ingredients, frequency, and duration was linked, but complete ingredient amounts and units were not verified.	The complete active composition, amounts/units of each ingredient, dosing records, and product-batch data for 2012.	Reconstruct a table of actual amounts and dosing frequency by ingredient, leave unverified composition empty, and assess the possibility of an isolated comparison.
10	Unverified	Full text not readStored summary read	N10 · Labeled and actual amountsWas the reported dose kept from being converted into a therapeutic dose for the single-active-ingredient product?Required	The reported amount for the 2014 product is 2.2 g/day, described as the content of 4 tablets. The manuscript does not use this as a verified therapeutic dose of B5 alone. The directly eligible monotherapy dose and actual adherence are unverified. S01 S03 S06	A reported product amount is available, but verified actual exposure to a single-active-ingredient product matching the question is unavailable.	Labeled-amount basis, frequency, actual use/adherence, diet, and other supplemental intake for the eligible single-active-ingredient product.	After reviewing adherence while separating labeled amounts from actual exposure, assess whether there are direct dose comparisons of the same formulation.
11	Unverified	Full text not readStored summary read	N11 · Duration and time pointsWere product observation periods distinguished from eligible single-active-ingredient time points?Required	Yang 2014 is preserved as 12 weeks, Capodice 2012 as 8 weeks, and Saki 2025's separate intramuscular comparison as 2 months. The duration and assessment time point of directly eligible monotherapy are unverified in facets. S01 S03 S04	The adjacent durations were read, but they cannot replace the single-active-ingredient time point in the original question.	Start/end dates, assessment schedules, duration of observation, and endpoint-specific timelines for the single-active-ingredient product.	Separate dosing, assessment, and analysis time points by report in a timeline, and review comparability of the same endpoint at the same time point.
12	Unverified	Full text not readStored summary read	N12 · Placebo and background treatmentWas the difference between the single-active-ingredient product and placebo under the same background treatment verified?Required	The original comparator is placebo under the same background treatment, but the detailed composition of the actual single-active-ingredient comparison is unverified. Yang is a related placebo-controlled product trial, while Saki's adapalene background is a comparison involving a different route. S01 S04	The design label placebo-controlled alone cannot verify sole-active-ingredient status or matching background conditions.	Complete composition of the single-active-ingredient product/placebo, common treatment by group, rescue treatment/changes, and adherence records.	Design a comparison of the single-active-ingredient product and a matching placebo under the same background treatment, and prespecify recording and analysis of changes in concomitant/rescue treatment.
13	Unverified	Full text not readStored summary read	N13 · Allocation and concealmentWere the actual allocation process and baseline balance verified?Required (causal efficacy)	Yang's original design is a randomized, double-blind, placebo-controlled study lasting 12 weeks, and Capodice is an uncontrolled, open-label study lasting 8 weeks. The archived summaries read in this review contain no review of sequence generation, allocation concealment, or baseline balance for a directly eligible single-active-ingredient product. S01 S03	Design labels from related product trials were not upgraded into verification of methods for a single-active-ingredient comparison.	Random sequence, concealment, group-specific baseline tables, and original methods text for the direct single-active-ingredient comparison.	Compare the methods and baseline tables against outcome-specific allocation/concealment questions, and separate unverified elements.
14	Met	Full text not readStored summary read	N14 · Baseline means and SDWere 15.3(8.9) and 17.3(14.3) kept from being used as effects?Required (numerical attribution)	The retained text reports the baseline inflammatory-lesion mean (SD) in Table 1 as 15.3(8.9) for the product group and 17.3(14.3) for the placebo group. This is a baseline comparison, not a treatment effect, endpoint value, or CI. S01	The original attribution to baseline, group, and mean/SD was preserved, and no new effect was calculated.	The baseline table's means/SDs, groups/time points, and denominators, and the endpoint/change results table for the outcome concerned.	Cross-check each numerical value in the table by group, time point, and statistic, and extract baseline values separately from treatment results.
15	Partly verified	Full text not readStored summary read	N15 · Endpoint typeWere inflammatory lesions separated from total lesions and other assessments?Required	Yang's primary endpoint is total lesions, while inflammatory lesions and other endpoints are reported as secondary. The original question concerns the between-group difference in change in inflammatory-lesion counts; the endpoint difference is separate. Total-lesion results were not used as inflammatory-lesion results. S01	The difference in endpoints was verified, but the precise lesion classifications, measurement methods, and target results table remain to be verified.	Lesion classifications, counting definitions, the primary/secondary endpoint table, and between-group results for each endpoint.	Specify inflammatory lesions as the prespecified endpoint of interest and report total lesions, noninflammatory lesions, and other scales as separate results.
16	Unverified	Full text not readStored summary read	N16 · Counting and blindingCan the actual procedures for lesion counting and assessor blinding be determined?Required	The retained original assessment records that the lesions themselves are the treatment target and are not reclassified as surrogate markers merely because they are counted by an observer. Yang's design is described as double-blind, but details of lesion-counting procedures and assessor blinding are currently unverified. S01	Endpoint classification and the design designation alone cannot substitute for verification of the actual measurement process.	Lesion-counting manual, assessor training/agreement, maintenance of blinding, and collection schedules by group.	Review blinded assessment and agreement in advance using standardized counting procedures, and record differences in measurement schedules between groups.
17	Partly verified	Full text not readStored summary read	N17 · Allocation and evaluation denominatorsWhich analyses do 48/41 and the group-specific 20/21 counts belong to?Required	S01 reports 48 allocated and 41 evaluated, with group-specific counts of 20/21. The original what_research explicitly states that the endpoint-specific analysis denominator for inflammatory lesions could not be verified. No group assignment for 20/21 or ITT denominator was added from this n field alone. S01	The original allocation/evaluation counts were preserved, but endpoint-specific denominators, group correspondence, and analysis definitions remain to be verified.	Flow diagram, group-specific allocation/completion/analysis table, endpoint-specific analysis n, and group identification.	Separate the flow table into allocation, completion, and target-endpoint analysis, and compare denominator links by group/time point.
18	Unverified	Full text not readStored summary read	N18 · Missing data and analysis populationsWere people who were not evaluated and the handling of ITT/PP verified?Required	S01's 48 allocated and 41 evaluated and S03's 11 enrolled and 10 completed are different data. The currently archived summaries did not verify group-specific reasons for missing inflammatory-lesion data or ITT/PP, imputation, and sensitivity handling. S01 S03	Only flow counts are available, without evidence on missing-data/analysis handling for the target outcome.	Reasons for loss to follow-up/discontinuation by group, ITT/PP definitions, missing-data handling, and sensitivity analyses.	Distinguish interest in the effect of assignment from the effect of adherence, and compare analysis plans/sensitivity analyses that include missing endpoint data.
19	Unverified	Full text not readStored summary read	N19 · Target between-group effectAre the between-group difference, P, and CI for inflammatory lesions with the single-ingredient intervention available?Required	The current primary_effect records for mean_difference, confidence_interval, p_value, and analysis sample size are all empty. The manuscript records that an eligible controlled result for the single-ingredient intervention and exact inflammatory-lesion endpoint values, between-group differences in change, CI, P, and endpoint-specific n could not be verified. S01 S02 S03	The empty values for the original target effect and analysis data were preserved as they were, without filling them with adjacent values.	Results table for the directly relevant single-ingredient intervention, including endpoint/change means, variances, group-specific n, analysis model, P, and CI.	In a single-ingredient intervention–placebo comparison with the same background treatment, report between-group estimates and intervals for the prespecified inflammatory endpoint by analysis population.
20	Unverified	Full text not readStored summary read	N20 · Variance and intervalsWas precision kept from being filled in using baseline SDs or significance for other endpoints?Required	The Table 1 values 15.3(8.9) and 17.3(14.3) are baseline means (SDs). The direct-effect CI and SE are empty in the current calculation record, and the precision axis also retains its original empty value. No new interval was constructed from these values. S01	Baseline variance and target-effect precision are separate, and the required direct interval is absent.	Variances of inflammatory-lesion change/endpoint values, group-specific n, and SE/CI appropriate to the analysis.	Compare change-score variances and intervals appropriate to the original analysis, and record limitations imposed by missing-data assumptions on interval interpretation.
21	Partly verified	Full text not readStored summary read	N21 · Favorable total-lesion valuesWere the outcomes and denominators to which P=0.0197 and 68.21% refer preserved?Required (preservation of related results)	Yang's total-lesion result P=0.0197 and the 68.21% wording were retained as originally reported. The formula and denominator for 68.21% are unclear, so it was not accepted as an additional reduction relative to placebo, and the total-lesion P was not assigned to inflammatory lesions. S01	The presence and limitations of the favorable values were verified, but their formula, denominator, and direct attribution remain to be verified.	Original total-lesion results table, calculation formula/denominator for 68.21%, group/time point, and effect direction.	Compare the wording's formula, denominator, group, and endpoint with the original table, and verify from the original definition whether it represents an additional effect relative to placebo.
22	Unverified	Full text not readStored summary read	N22 · Separating ingredient contributionsCan the contribution of B5 be separated from the combination product's effect?Required	The current manuscript distinguishes the effects of pantothenic acid alone from those of products containing pantothenic acid. The sole-active-ingredient status of the 2014 product is unverified, and the 2012 product has multiple ingredients. The separate contribution of B5 could not be verified from the results for both products. S01 S03	Product comparisons and within-group changes are available, but there are no data separating the contribution of the sole active ingredient.	Full composition, ingredient-specific comparators or appropriate factorial comparisons, and common-background data.	Review a single-ingredient comparison in which only B5 differs, or a factorial design with ingredient contributions defined in advance.
23	Partly verified	Full text not readStored summary read	N23 · Uncontrolled within-group resultsWas the 2012 change of 20.45→11.18 kept from being converted into a between-group effect?Required (preservation of related results)	Capodice 2012 is an uncontrolled, open-label study over 8 weeks, with 11 enrolled and 10 completed as reported. The global-lesion change of 20.45→11.18 is a within-group change with a multi-ingredient product, not an inflammatory-lesion effect relative to placebo. S03	The original favorable within-group result was preserved, but the comparator, sole-active-ingredient status, and target endpoint differ from the original question.	The 2012 results table, global-lesion definition, within-group analysis, flow of 11 enrolled/10 completed, and detailed composition.	Extract within-group results separately, and compare alternative explanations involving temporal change, regression, and concurrent treatment against comparative data.
24	Partly verified	Full text not readStored summary read	N24 · Other routes and no detected differenceWas Saki's P=0.476 kept from being used as an effect of 0 for oral single-ingredient supplementation?Required (boundaries for contrary results)	Saki 2025 is described in the original KO as a study adding intramuscular dexpanthenol to topical adapalene, while the original paper title says Pantothenic Acid. The single-blind design, 2 months, analysis groups of 31/28, and between-group P=0.476 for inflammatory-lesion endpoint values are preserved. This is a nonsignificant result for a different route/molecule and is not used as an oral B5 effect of 0 or repeated counterevidence. S04	The separate result and exclusion boundaries were linked, but the external formulation/molecule, denominators, and original table were not newly verified.	Saki's actual molecule/formulation, intramuscular administration, adapalene background, analysis groups/time points, and original results table.	Compare differences in the reported title, actual administered formulation, route, background, and endpoint timing to distinguish the basis for judging directness.
25	Unverified	Full text not readStored summary read	N25 · Historical hypotheses and bibliographic recordsWas the Leung bibliographic lead kept from being converted into an eligible RCT result?Required (candidate boundaries)	Leung 1995 is classified in the original evidence as a historical hypothesis/related report; the directly relevant controlled design, n, and between-group inflammatory-lesion results in the original text are unverified. Historical access is recorded as metadata_search_index, and the publisher's full text is recorded as not having been obtained. S05	A bibliographic identity is available, but no material links it to an eligible comparative result.	Leung's original text, actual study design/population, single-ingredient oral intervention, and between-group inflammatory-lesion results.	If the original text is acquired, separate hypotheses from observational/trial results and compare them with the current question using an eligibility table.
26	Met	Full text not readStored summary read	N26 · Legacy and other endpointsWere S09–S11 kept from being repurposed as direct acne results?Required (attribution of related material)	S09 is a comparison involving calcium pantothenate and other treatments for female hair loss, S10 is a review of topical dexpanthenol, and S11 is a bibliographic record for a topical barrier/hydration study. The original citation specifies that only sources and boundaries were carried over from the previous 028 and that these are not numerical clinical evidence for this review. The current external originals and legacy 028 were not read. S09 S10 S11	The current citations verified the scope of carryover and the boundary that these concern different questions. The efficacy of those studies was not newly verified.	The original citations' populations, routes, and endpoints, and the scope of legacy carryover; original results if needed.	Separate each carried-over citation into a population, molecule, route, and endpoint table to distinguish discovery context from direct results.
27	Unverified	Full text not readStored summary read	N27 · Registration and analysis plansCan the planned inflammatory endpoints/time points be compared with the reports?Required	The original limitations explicitly state that registration/analysis plans are unverified, and the nct values in evidence are empty. The original search summary reports some registration/API access failures. S02 is a single summary slide, not a composition certificate or protocol. No registration/API lookup was performed in this review. S01 S02 S03 S04	No material permits direct comparison of advance plans with actual endpoints/denominators.	Official registration history, protocol, SAP, reasons for endpoint changes, and reported results.	Compare initial registration/change histories, protocols, and SAP with report endpoints, time points, and analyses step by step.
28	Partly verified	Full text not readStored summary read	N28 · Funding and conflicts of interestWere sponsorship, institutions, declarations, and unverified information distinguished?Supplementary; required for claims of independence	S01 reports Avilan research funding, Nutraceutical Medical Research publication fees, and a declaration of no conflicts of interest. S03 is affiliated with Nutraceutical Medical Research, while details of funding, product provision, employment/patents, and COI are unverified. S04 is retained with Shiraz University, Actoverco, and a declaration of no conflicts of interest; S05 is retained with funding unverified. S01 S03 S04 S05	The reported funding/declarations were verified, but not all employment, patents, or sponsor roles were verified.	Research funding/publication fees, product provision, author employment/patents, COI, and sponsor roles in the research.	Compare funding sources, institutions, employment, patents, and sponsor roles by report in a table, and preserve results regardless of their direction.
29	Unverified	Full text not readStored summary read	N29 · Direct replication and differencesWere differences among related studies kept from being counted as independent replications of single-active-ingredient treatment?Required (interpretation of replication)	The original assessment limits its statement to not having verified a directly eligible controlled trial of a single active ingredient for the fixed endpoint, and records the existence of related human studies as true. Positive combination-product results, uncontrolled within-group results, nonsignificant results from another route, and hypothesis candidates were not added together as direct replications of single-active-ingredient treatment. S01 S02 S03 S04 S05	Eligible single-active-ingredient results and independence information needed for a direct replication comparison are unavailable.	Unique trial identity, eligibility/results tables, single-active-ingredient composition, each endpoint/time point, and information on independent institutions.	First compare eligibility and outcome differences by trial, then review direct independent replication separately after deduplication.
30	Unverified	Full text not readStored summary read	N30 · Clinical importanceIs there evidence for judging the clinical importance of a difference in lesion counts?Required (interpretation of importance)	The original assessment limitations leave MCID unverified, and direct effects/CI are also empty. Total-lesion P=0.0197 and 68.21% were not used as criteria for the clinical sufficiency of single-active-ingredient inflammatory-lesion results. S01	Both the direct effect and the important-difference criterion are unverified, so sufficiency cannot be interpreted.	Between-group effects/CI for the target inflammatory lesions, evidence of importance from the patient's perspective, and prespecified criteria.	Review criteria linking patient experience to lesion differences, then present their relationship to the original intervals within a prespecified interpretation framework.
31	Met	Full text not readStored summary read	N31 · Mechanistic and clinical boundariesWere NAD/skin-hydration results kept from being used as effects on inflammatory lesions?Supplementary; required for expansion to other clinical questions	The original classification is a P endpoint in which inflammatory lesions themselves are the treatment target. The presence of pantothenic acid, NAD/cellular mechanisms, or topical moisturization does not demonstrate reduction of inflammatory lesions with an oral single active ingredient, and is not extended to effects on quality of life, scarring, or other events. S01 S10 S11	The original P classification was linked to the boundary against substitution by related measures. No new efficacy judgment for events was created.	Definition of the selected endpoint and the actual evidence and interpretive scope for each related mechanism/other clinical measure.	Record mechanistic explanations and clinical lesion comparisons as separate lines of evidence, and handle new questions such as quality of life or scarring through a separate boundary review.
32	Not applicable	Full text not readStored summary read	N32 · Obligations for expanded questionsAre optimal dose, persistence after discontinuation, and subgroup effects imposed as mandatory?Supplementary; required only for the relevant expansion	The original /ko/effect is the single question of reducing inflammatory lesion counts in adults with mild-to-moderate facial acne; it makes no claim about optimal dose, persistence after discontinuation, or efficacy in specific subgroups. Only a blanket obligation to conduct these expanded studies is not applicable. S01 S03	The obligation for expansion outside the narrow assessed question was treated as not applicable. Unverified actual single-active-ingredient dose, duration, and population remain unchanged.	Direct dose comparisons, discontinuation/long-term follow-up, and prespecified subgroup and interaction data when making expanded claims.	If an expanded question is raised, separately design direct dose comparisons, follow-up after discontinuation, or a prespecified effect-modification plan.
33	Unverified	Full text not readStored summary read	N33 · Adverse-event recordsWas the lack of reported serious adverse events in a short combination-product study kept from being turned into safety?Supplementary; required for safety interpretation	The original caution wording states that the lack of reported serious adverse events in the small 12-week combination-product trial was not generalized to long-term safety of a single-active-ingredient product. The current archived summaries contain no table of adverse events by arm, collection methods, denominators, or discontinuations for a directly relevant single-active-ingredient product. S01 S03 S06	The safety boundary is preserved, but quantitative harm and completeness-of-collection data for a directly relevant single-active-ingredient product are unverified.	Tables of adverse events by arm, event/person counts, collection methods, denominators/durations, and discontinuation/missing data for a single-active-ingredient product.	Plan systematic harm collection and follow-up of discontinuations in the same formulation, population, and duration, and report persons/events and denominators separately.
34	Met	Full text not readStored summary read	N34 · Nutrition and risk examplesWere the meanings of 5 mg/day, 10 g/day, and the absence of an established UL distinguished?Supplementary; required for defining safety scope	The preserved safety wording describes the adult adequate intake of 5 mg/day as a nutritional reference value and NIH's 10 g/day as an example associated with diarrhea/gastrointestinal discomfort. The 10 g/day value is not a toxicity threshold or intake recommendation, and the absence of an established UL does not mean unlimited safety. S06	The original numbers and interpretive limitations were carried over. This is not new safety certification or personal dosing instructions.	Relevant sections of official nutrition/excess-intake risk documents and safety data for the actual formulation, population, and exposure.	Compare the nature of official reference values and examples of harm-associated exposure by formulation, population, and duration, keeping them separate from personal recommendations.
35	Unverified	Full text not readStored summary read	N35 · Long-term use and vulnerable groupsWere safety gaps for high doses, special populations, and interactions retained?Supplementary; required for the relevant safety expansion	The manuscript explicitly states that the safety of high-dose use for acne in pregnancy, lactation, children, and liver/kidney disease is unverified. The statement that no important drug interactions are known does not exclude all interactions. Short combination-product data were not extended to long-term single-active-ingredient use. S01 S06	The original gaps are retained because direct verification of expanded safety data is absent.	Data on long-term use/special populations, underlying diseases, concomitant medications, interactions, and discontinuation/recovery for single-active-ingredient formulations.	Review designs for harm follow-up that distinguish populations, durations, and concomitant exposures, and report information gaps for vulnerable groups separately.
36	Met	Full text not readStored summary read	N36 · Search and update scopeWas the lack of direct verification kept from being extended to worldwide absence or a current search?Required	The original reference date is 2026-09-15, and the judgment is limited to targeted search-engine searches, citation tracking, and accessible original texts. Some PubMed and registration/API failures and unacquired full texts are disclosed. The conversion in this review on 2026-10-05 involves reading archived materials, with no new search. New single-active-ingredient trials, composition information, target outcomes/SAP, corrections, or safety information are reasons for updates under the same ID/URL. S01 S02 S03 S04 S05 S06	The scope verified at that time was distinguished from and linked to the current work and specific reasons for updates.	Original search/selection ledger, registration/access records, correction/retraction information, and current original-text versions.	If new material becomes available within an authorized scope, distinguish search/access events, additions of evidence, and revisions of conditions, and re-review the linked rows.
37	Met	Full text not readStored summary read	N37 · Preservation of the original judgmentWere the scope of the original ?, empty values, axes, and direct-human-evidence flags preserved?Required (preservation contract)	The original grade is ?, score is empty, and the 7 axes are B/P/the remaining five empty values. no_human_study=true and human_study_exists=false refer to directly eligible controlled trials of a single active ingredient for the fixed endpoint, while the existence of related human studies is true. The numerical and denominator fields of primary_effect are empty, and the original safety is Caution. Historical first_published_at and ready metadata do not mean publication on the website was completed in this review. S01 S03 S04 S05	The original values and scope were linked unchanged, without creating new scores, grades, effects, or publication certification.	The gate scope of the original grade/score, axes, and assessment_profile, together with self-review and publication metadata.	Compare the preserved original text and display values, and treat only data/table-conversion errors as separate correction events.

No items match your search or filter.

37 itemsWhat the statuses mean

Assessment scope

Stored-material review date: 2026-10-05
Original evidence date: 2026-09-15
Scope actually checked: Archived Korean and English manuscripts and case-specific condition and application records. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the archived material was checked, not the date of a search for the latest clinical literature.
Population: Adults with mild-to-moderate facial acne; distinguished from efficacy in correcting deficiency
Ingredient, formulation and route: Pantothenic acid (vitamin B5) as the sole active ingredient; the calcium salt requires separate verification · Oral · Oral formulation with a single active ingredient — exact salt, tablet/capsule, and release formulation unverified
Dose: Unverified — the directly eligible monotherapy dose could not be verified
Comparator: Placebo with the same background treatment — detailed composition of the actual single-active-ingredient comparison is unverified
Measured outcome: Between-group difference in change in inflammatory lesion counts; the endpoint difference is reported separately, and eligible numerical results are unverified
Duration: Unverified — the assessment time point for directly eligible monotherapy is unverified
Questions outside this scope: Calcium pantothenate and the free acid are not automatically treated as equivalent; dexpanthenol and topical/intramuscular material are kept within the boundaries of adjacent evidence.; The legacy 028 or reference files are not labeled as directly read in this review, and their clinical numerical values are not inherited.; Unverified actual doses and assessment time points for the single-active-ingredient product remain under the separate required conditions N10/N11 and are not erased by this Not applicable status.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Yang et al. 2014. A Randomized, Double-Blind, Placebo-Controlled Study of a Novel Pantothenic Acid-Based Dietary Supplement in Subjects with Mild to Moderate Facial Acne

Source

Material type: related_controlled_product
Materials actually read: The relevant Korean/English summaries and bibliographic records in the archived manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: 48 people allocated, 41 evaluable, with reported group counts of 20/21. The total-lesion P=0.0197 and the expression 68.21%, along with baseline inflammatory-lesion means (SD) of 15.3(8.9)/17.3(14.3), are preserved. Complete composition, single-active-ingredient status, and the target between-group inflammatory-lesion effect are unverified.
Record level: This is content recorded in the archived manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Publisher's article web full text	Unverified (no lookup in this review)	Not attempted in this review	Not read	12-week total-lesion/inflammatory-lesion report on a related product whose single-active-ingredient status is unverified; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: full_text. Historical location in the reference bibliography: Methods; Results; Table 1 and Figures 1–3, printed pp. 95–97; Acknowledgments, p. 100 Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.
DOI identifier and publisher-link entry point	Unverified (no lookup in this review)	Not attempted in this review	Not read	12-week total-lesion/inflammatory-lesion report on a related product whose single-active-ingredient status is unverified; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: Unverified. Historical location in the reference bibliography: Methods; Results; Table 1 and Figures 1–3, printed pp. 95–97; Acknowledgments, p. 100 The original citation's historical access is a record in the context of the article report. The historical access/reading level of this DOI identifier-link entry point itself was not separately verified. Currently, access has not been attempted and it has not been read. Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.

S02 · Yang 2014 electronic supplementary material — summary slide

Source

Material type: same_study_supplement
Materials actually read: The relevant Korean/English summaries and bibliographic records in the archived manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: The original location explicitly describes a single-page summary slide, not a composition certificate or protocol. It is grouped in the same report family as S01 and is not counted as a separate trial or participants.
Record level: This is content recorded in the archived manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Article supplementary summary-slide PDF	Unverified (no lookup in this review)	Not attempted in this review	Not read	Supplementary summary of the same paper as S01; not an independent replication; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: full-text PDF document. Historical location in the reference bibliography: One-page summary slide, not a formulation certificate or protocol Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.

S03 · Capodice JL. 2012. Feasibility, Tolerability, Safety and Efficacy of a Pantothenic Acid Based Dietary Supplement in Subjects with Mild to Moderate Facial Acne Blemishes

Source

Material type: related_uncontrolled_product
Materials actually read: The relevant Korean/English summaries and bibliographic records in the archived manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: Uncontrolled, open-label, 8 weeks, with 11 enrolled and 10 completing. The product contains other vitamins and L-carnitine, with 2 tablets taken 2 times daily. The total-lesion change of 20.45→11.18 is a within-group result, not an inflammatory-lesion effect versus placebo. Identity with the 2014 batch is unverified.
Record level: This is content recorded in the archived manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Article-sharing and full-text mirror page	Unverified (no lookup in this review)	Not attempted in this review	Not read	Multicomponent product and within-group change in total lesions; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: full_text_mirror. Historical location in the reference bibliography: Journal of Cosmetics, Dermatological Sciences and Applications 2(3):132–135; section 2.2 (p.133), section 3/Table 1 (p.134) Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.
DOI identifier and publisher-link entry point	Unverified (no lookup in this review)	Not attempted in this review	Not read	Multicomponent product and within-group change in total lesions; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: Unverified. Historical location in the reference bibliography: Journal of Cosmetics, Dermatological Sciences and Applications 2(3):132–135; section 2.2 (p.133), section 3/Table 1 (p.134) The original citation's historical access is a record in the context of the article report. The historical access/reading level of this DOI identifier-link entry point itself was not separately verified. Currently, access has not been attempted and it has not been read. Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.

S04 · Saki et al. 2025. Efficacy of Intramuscular Pantothenic Acid in the Treatment of Acne Vulgaris: A Single Blind Randomized Clinical Trial

Source

Material type: different_route_molecule
Materials actually read: The relevant Korean/English summaries and bibliographic records in the archived manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: The original KO describes intramuscular dexpanthenol added to topical adapalene, while the citation title says Pantothenic Acid. Single-blind, 2 months, analysis groups 31/28, between-group endpoint-value P=0.476. This is not used as evidence of an oral B5 effect of 0 or as replicated refutation.
Record level: This is content recorded in the archived manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Publisher's article web full text	Unverified (no lookup in this review)	Not attempted in this review	Not read	Comparison of inflammatory-lesion endpoint values using a different route, molecule, and background; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: full_text. Historical location in the reference bibliography: Methods 2.1–2.4; Table 5; Funding and Conflicts of Interest Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.
DOI identifier and publisher-link entry point	Unverified (no lookup in this review)	Not attempted in this review	Not read	Comparison of inflammatory-lesion endpoint values using a different route, molecule, and background; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: Unverified. Historical location in the reference bibliography: Methods 2.1–2.4; Table 5; Funding and Conflicts of Interest The original citation's historical access is a record in the context of the article report. The historical access/reading level of this DOI identifier-link entry point itself was not separately verified. Currently, access has not been attempted and it has not been read. Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.

S05 · Leung LH. 1995. Pantothenic acid deficiency as the pathogenesis of acne vulgaris

Source

Material type: hypothesis_discovery_unverified
Materials actually read: The relevant Korean/English summaries and bibliographic records in the archived manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: The comparison design, n, and between-group inflammatory-lesion results for a single active ingredient in the original text are unverified. Historical metadata_search_index and the unacquired publisher full text are preserved, without turning the citation into eligible RCT results.
Record level: This is content recorded in the archived manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
PubMed bibliographic and indexing page	Unverified (no lookup in this review)	Not attempted in this review	Not read	Historical hypothesis/bibliographic lead; direct comparison unverified; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: metadata_search_index. Historical location in the reference bibliography: PubMed indexed title/DOI; full publisher article not obtained Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.
DOI identifier and publisher-link entry point	Unverified (no lookup in this review)	Not attempted in this review	Not read	Historical hypothesis/bibliographic lead; direct comparison unverified; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: Unverified. Historical location in the reference bibliography: PubMed indexed title/DOI; full publisher article not obtained The original citation's historical access is a record in the context of the article report. The historical access/reading level of this DOI identifier-link entry point itself was not separately verified. Currently, access has not been attempted and it has not been read. Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.

S06 · NIH Office of Dietary Supplements. Pantothenic Acid — Health Professional Fact Sheet

Source

Material type: official_nutrition_safety
Materials actually read: The relevant Korean/English summaries and bibliographic records in the archived manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: The adequate intake of 5 mg/day, the gastrointestinal harm example of 10 g/day, the absence of an established UL, and the interaction scope in the original safety summary are preserved. This is not material newly verifying acne efficacy, therapeutic doses, toxicity thresholds, or unlimited safety.
Record level: This is content recorded in the archived manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
NIH ODS official web document	Unverified (no lookup in this review)	Not attempted in this review	Not read	Explanation of nutrition, formulations, excess-intake risks, and interactions; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: full_text. Historical location in the reference bibliography: Table 1; Dietary supplements; Health Risks from Excessive Pantothenic Acid; Interactions with Medications Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.

S09 · Siavash M, Tavakoli F, Mokhtari F. 2017. Comparing the Effects of Zinc Sulfate, Calcium Pantothenate, Their Combination and Minoxidil Solution Regimens on Controlling Hair Loss in Women: A Randomized Controlled Trial. Journal of Research in Pharmacy Practice; PMID 28616431 / DOI 10.4103/jrpp.JRPP_17_17.

Source

Material type: other_population_endpoint_inherited
Materials actually read: The relevant Korean/English summaries and bibliographic records in the archived manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: This is bibliographic information on a comparison involving zinc/calcium pantothenate, a combination product, and minoxidil for female hair loss. The current citation explicitly inherits only the source/boundaries from legacy 028 and is not evidence for clinical numbers in this review.
Record level: This is content recorded in the archived manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
PMC article web full text	Unverified (no lookup in this review)	Not attempted in this review	Not read	Only the source/boundaries from legacy 028 are inherited; these are not acne numbers; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: inherited_local_record. Historical location in the reference bibliography: reference/legacy_028.json /citations/1 Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.

S10 · Ebner F, Heller A, Rippke F, Tausch I. 2002. Topical use of dexpanthenol in skin disorders. American Journal of Clinical Dermatology; PMID 12113650 / DOI 10.2165/00128071-200203060-00005.

Source

Material type: topical_review_inherited
Materials actually read: The relevant Korean/English summaries and bibliographic records in the archived manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: This is bibliographic information for a review of topical dexpanthenol in skin diseases. Only the source/boundaries were inherited from legacy 028, and it is not used as an inflammatory-lesion outcome for an oral single active ingredient.
Record level: This is content recorded in the archived manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
PubMed bibliographic and indexing page	Unverified (no lookup in this review)	Not attempted in this review	Not read	Legacy bibliographic boundaries for a review of topical use and a different molecule; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: inherited_local_record. Historical location in the reference bibliography: reference/legacy_028.json /citations/3 Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.

S11 · Gehring W, Gloor M. 2000. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study. Arzneimittelforschung (Drug Research); PMID 10965426 / DOI 10.1055/s-0031-1300268.

Source

Material type: topical_hydration_inherited
Materials actually read: The relevant Korean/English summaries and bibliographic records in the archived manuscript were read. The linked external original materials were not read in this review.
Findings recorded in the stored summary: This is bibliographic information for research on barrier function and stratum-corneum hydration with topical dexpanthenol. Only the source/boundaries were inherited from legacy 028, and it is not a direct inflammatory-lesion result for oral acne treatment.
Record level: This is content recorded in the archived manuscript. It is not the result of a new comparison with current external original materials.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
PubMed bibliographic and indexing page	Unverified (no lookup in this review)	Not attempted in this review	Not read	Legacy bibliographic boundaries for topical barrier/hydration endpoints; The physical material type, historical access, and current reading level are distinguished. The original citation's bibliographic/URL identity is preserved; current external content/bytes are unverified. The original URL was preserved unchanged. No link access or verification of the identifier/physical document was performed in this review. A DOI entry point does not mean that the full text was acquired. Historical access dates for each material are unverified. The archived manuscript review date 2026-09-15 is not the access date of this original material file. Historical access level of this material itself: inherited_local_record. Historical location in the reference bibliography: reference/legacy_028.json /citations/4 Bibliographic access records are not inherited as access to a separate full text or underlying material. This does not mean that external original materials were acquired or full texts read in this review.

Report counts versus independent study counts

The current original evidence family labels and the same-paper linkage of S01/S02 are preserved. Independent trials, direct replications, and a summed participant total are not newly established. F01 (S01, S02): Yang 2014 main text and supplementary slide from the same study. Single-active-ingredient status and direct inflammatory-lesion results are unverified. / F02 (S03): 2012 multicomponent, uncontrolled, total-lesion within-group results; identity with the 2014 batch is unverified / F03 (S04): 2025 comparison of inflammatory-lesion endpoint values with intramuscular administration and a different molecule/background / F04 (S05): 1995 hypothesis/bibliographic candidate; original comparative design/single-active-ingredient results are unverified. The S01 main text and S02 supplementary summary concern the same study; report counts are not summed as independent trial counts or total participant counts.

Review criteria

Version NGM-v3099-ORAL-SINGLE-B5-ACNE-INFLAMMATORY-1.0 · Criteria record date 2026-10-05. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which single question is linked to the original verdict URL?

Required materials and conditions: The current assessment target, facets, empty subclaims, canonical URL, and identity of the related 028.
Conditions for verification: Link the original /ko/effect to adult facial acne, oral pantothenic acid as the sole active ingredient, inflammatory lesion counts, and a placebo comparison with the same background treatment.
Requirement and applicability: Required
Application exceptions: Korean/English versions and adjacent outcomes such as total lesions do not automatically generate separate independent claims.
Why this condition is needed: Required to avoid merging other skin effects or the existing mixed claim 028 into the efficacy of the single ingredient assessed here.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed — internal adaptation for a separate claim. This is not official methodological certification.

N02 · Was the effect of pantothenic acid alone distinguished from the product effect?

Required materials and conditions: Material documenting all active ingredients, the exact salt, actual route, product, and batch of the single-active-ingredient formulation.
Conditions for verification: Verify whether the exact active ingredient, molecule, and route match the fixed question, and separate results from combination products.
Requirement and applicability: Required
Application exceptions: Calcium pantothenate and the free acid are not automatically treated as equivalent; dexpanthenol and topical/intramuscular material are kept within the boundaries of adjacent evidence.
Why this condition is needed: The presence of an ingredient alone cannot establish its isolated effect.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed — internal adaptation for a sole active ingredient. This is not official methodological certification.

N03 · Was summary reading in this review distinguished from historical access to original texts?

Required materials and conditions: The preserved URL, location, and access_level for each citation, and any records of individual access dates/acquired copies, if available.
Conditions for verification: Separate the currently archived summaries actually read, each report's historical access_level, external access not attempted/material not read in this review, and the absence of access dates.
Requirement and applicability: Required
Application exceptions: Because the original citation has no access date, leave the value empty and record the global verified_date separately as the material review date.
Why this condition is needed: Required to avoid mistaking an external link or historical full_text for full-text reading in this review.
Referenced methods: Material collection/selection principles in M04 §4.5–4.6; separation of access and reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design — internal adaptation for the level of reading. This is not official methodological certification.

N04 · Were the Yang main text and supplementary slide kept from being double-counted as trials?

Required materials and conditions: Each report's DOI, year, trial identity, supplementary-material linkage, and original evidence family_id.
Conditions for verification: Link S01/S02 to the same 2014 Yang family, and distinguish the original F01–F04 labels from a count of independent trials.
Requirement and applicability: Required
Application exceptions: S03 is the original F02 uncontrolled material from 2012. Even with the same Pantothen brand, batch identity with S01 is unverified.
Why this condition is needed: Required to avoid adding a paper and its appendix as independent replications or assuming that materials from different years of the same brand concern an identical batch.
Referenced methods: Distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application — internal adaptation for report and trial families. This is not official methodological certification.

N05 · Does the material directly match adults with mild-to-moderate facial acne?

Required materials and conditions: Tables of diagnosis, age/severity distributions, inclusion/exclusion, and baseline treatment in single-active-ingredient trials.
Conditions for verification: Compare diagnosis, age, severity, lesion location, inclusion/exclusion, and the actual directly eligible population.
Requirement and applicability: Required
Application exceptions: The phrase mild-to-moderate facial acne in the title of an adjacent study is not extended into verification of all actual population details.
Why this condition is needed: The label facial acne alone does not establish that populations and clinical selection are the same.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed — internal adaptation for population and selection. This is not official methodological certification.

N06 · Was the hypothesis of deficiency correction distinguished from efficacy for acne in general?

Required materials and conditions: Baseline nutritional status, methods of identifying deficiency, and direct comparative results within that stratum.
Conditions for verification: Distinguish baseline pantothenic acid status, deficiency diagnosis, and correction outcomes from a comparison of monotherapy for acne.
Requirement and applicability: Supplementary; required for extension to deficiency
Application exceptions: Unverified baseline status is not filled in as normal or deficient. The S05 hypothesis is not a single-active-ingredient RCT with results.
Why this condition is needed: Required to avoid transferring a deficiency hypothesis to efficacy in an unverified general acne population.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed; question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed — internal adaptation for the deficiency boundary. This is not official methodological certification.

N07 · Were the salt, formulation, and manufacturing batch of the eligible single-active-ingredient product verified?

Required materials and conditions: Trial-batch manufacturing/composition certificates, complete label, salt and labeled-amount basis, and formulation-quality data.
Conditions for verification: Link the exact salt, manufacturing source, purity, batch, release formulation, and tablet/capsule to the actual trial product.
Requirement and applicability: Required
Application exceptions: The efficacy and doses of the calcium salt and free acid are not converted as equivalent. The presence of excipients alone does not establish that a product has multiple active ingredients.
Why this condition is needed: Product names and labeled amounts alone cannot establish the actual sole active ingredient or exposure.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed — internal adaptation for salt, batch, and quality. This is not official methodological certification.

N08 · Can the sole-active-ingredient status of the 2014 Pantothen product be verified?

Required materials and conditions: The complete active composition, exact salt, and batch certificate for the 2014 batch, and comparator ingredients.
Conditions for verification: Verify all active ingredients in the relevant 2014 trial batch and assess whether its effect can be separately attributed to B5.
Requirement and applicability: Required
Application exceptions: The fact that the 2012 product had multiple ingredients does not establish that the 2014 batch was identical.
Why this condition is needed: Required to avoid accepting the product effect in a related RCT as the effect of the selected ingredient alone.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application — internal adaptation for 2014 product composition. This is not official methodological certification.

N09 · Were the other ingredients and dosing of the 2012 product distinguished?

Required materials and conditions: The complete active composition, amounts/units of each ingredient, dosing records, and product-batch data for 2012.
Conditions for verification: Attribute the multiple ingredients, L-carnitine, and dosing frequency in 2012 and the 8-week observation to that product alone.
Requirement and applicability: Required (attribution of related material)
Application exceptions: Complete composition or unit extractions absent from the current archived summaries are not supplemented from old ledgers or the brand name.
Why this condition is needed: Required to avoid repurposing within-group results for a combination product as comparative efficacy of pantothenic acid alone.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application — internal adaptation for the 2012 combination product. This is not official methodological certification.

N10 · Was the reported dose kept from being converted into a therapeutic dose for the single-active-ingredient product?

Required materials and conditions: Labeled-amount basis, frequency, actual use/adherence, diet, and other supplemental intake for the eligible single-active-ingredient product.
Conditions for verification: Distinguish the product's reported amount from the actual active amount, adherence, and total intake for the single-active-ingredient product.
Requirement and applicability: Required
Application exceptions: Salt conversions, actual intake, and optimal doses absent from the original material are not calculated.
Why this condition is needed: Required to avoid presenting the adjacent product's 2.2 g/day as a verified dose for acne treatment with the single ingredient alone.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.1–3.2.4; details on dose, duration, and effect modification are internally designed — internal adaptation for labeled and actual amounts. This is not official methodological certification.

N11 · Were product observation periods distinguished from eligible single-active-ingredient time points?

Required materials and conditions: Start/end dates, assessment schedules, duration of observation, and endpoint-specific timelines for the single-active-ingredient product.
Conditions for verification: Attribute 12 weeks, 8 weeks, and 2 months to their respective reports, and keep treatment/assessment time points for the eligible single-active-ingredient product separate.
Requirement and applicability: Required
Application exceptions: S04's 2 months are not newly converted to 8 weeks, and nominal duration is not assumed to establish actual exposure or complete follow-up.
Why this condition is needed: Required to avoid combining adjacent comparisons of different durations into a direct effect at a single time point.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.1–3.2.4; details on dose, duration, and effect modification are internally designed — internal adaptation for duration and time points. This is not official methodological certification.

N12 · Was the difference between the single-active-ingredient product and placebo under the same background treatment verified?

Required materials and conditions: Complete composition of the single-active-ingredient product/placebo, common treatment by group, rescue treatment/changes, and adherence records.
Conditions for verification: Separate placebo composition, concomitant/rescue treatment, adherence, and deviations from the difference in the sole active ingredient.
Requirement and applicability: Required
Application exceptions: Compare the effect of interest and actual management in each group rather than requiring complete identity of all changes in both groups.
Why this condition is needed: Required to avoid attributing contributions from concurrent ingredients or other treatments to pantothenic acid alone.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application — internal adaptation for placebo and background treatment. This is not official methodological certification.

N13 · Were the actual allocation process and baseline balance verified?

Required materials and conditions: Random sequence, concealment, group-specific baseline tables, and original methods text for the direct single-active-ingredient comparison.
Conditions for verification: Compare the allocation method, concealment, and baseline balance for the selected result separately from the study label.
Requirement and applicability: Required (causal efficacy)
Application exceptions: Preserve the uncontrolled S03 material as well, and do not automatically assign Not applicable for crossover/cluster design when the direct design is unverified.
Why this condition is needed: The labels randomized and double-blind alone cannot establish that all allocation and confounding problems were resolved.
Referenced methods: M08 §8.1–8.2.3; internal application — internal adaptation for allocation and concealment. This is not official methodological certification.

N14 · Were 15.3(8.9) and 17.3(14.3) kept from being used as effects?

Required materials and conditions: The baseline table's means/SDs, groups/time points, and denominators, and the endpoint/change results table for the outcome concerned.
Conditions for verification: Distinguish the baseline inflammatory-lesion means and SDs in Table 1 from endpoint values, differences in change, SE, and CI.
Requirement and applicability: Required (numerical attribution)
Application exceptions: Do not newly calculate endpoint differences, differences in change, or CI from baseline SDs and sample sizes.
Why this condition is needed: Needed to avoid converting baseline lesion counts or parenthesized SDs into single-ingredient effects and precision values.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.1–8.2.3; internal application — internal adaptation for baseline means/SDs. This is not official methodological certification.

N15 · Were inflammatory lesions separated from total lesions and other assessments?

Required materials and conditions: Lesion classifications, counting definitions, the primary/secondary endpoint table, and between-group results for each endpoint.
Conditions for verification: Separate the definitions/priorities of inflammatory-lesion counts, total lesions, noninflammatory lesions, and other clinical assessments.
Requirement and applicability: Required
Application exceptions: Do not fill in values or priorities for other scales, such as IGA, that are absent from the currently archived summaries.
Why this condition is needed: Needed to avoid automatically substituting total-lesion results for the original inflammatory-lesion effect.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application — internal adaptation for endpoint types. This is not official methodological certification.

N16 · Can the actual procedures for lesion counting and assessor blinding be determined?

Required materials and conditions: Lesion-counting manual, assessor training/agreement, maintenance of blinding, and collection schedules by group.
Conditions for verification: Verify inflammatory-lesion assessors, counting rules, assessment time points, blinding, and measurement differences between groups.
Requirement and applicability: Required
Application exceptions: Do not repurpose the double-blind designation as verification of actual lesion-assessor blinding or measurement limitations.
Why this condition is needed: Needed to avoid judging a measurement to be objective or a surrogate endpoint merely because it is called an observer count.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; internal application — internal adaptation for counting/blinding. This is not official methodological certification.

N17 · Which analyses do 48/41 and the group-specific 20/21 counts belong to?

Required materials and conditions: Flow diagram, group-specific allocation/completion/analysis table, endpoint-specific analysis n, and group identification.
Conditions for verification: Distinguish allocation, evaluation, and group-specific reported counts from the inflammatory-lesion analysis denominator, and do not infer group correspondence.
Requirement and applicability: Required
Application exceptions: Do not newly map the group-specific 20/21 order in the current n field to product/placebo without the original material.
Why this condition is needed: Needed to avoid immediately converting an evaluable sample into the target endpoint's ITT denominator or group-specific participants.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application — internal adaptation for allocation/evaluation denominators. This is not official methodological certification.

N18 · Were people who were not evaluated and the handling of ITT/PP verified?

Required materials and conditions: Reasons for loss to follow-up/discontinuation by group, ITT/PP definitions, missing-data handling, and sensitivity analyses.
Conditions for verification: Link reasons for missing data/discontinuation, their distribution by group, analysis populations, and imputation/sensitivity handling to the target endpoint.
Requirement and applicability: Required
Application exceptions: Do not arbitrarily assign ITT or PP if the original text does not specify the analysis.
Why this condition is needed: Needed to avoid transferring selected evaluable results to an effect among everyone allocated.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application — internal adaptation for missing data/analysis populations. This is not official methodological certification.

N19 · Are the between-group difference, P, and CI for inflammatory lesions with the single-ingredient intervention available?

Required materials and conditions: Results table for the directly relevant single-ingredient intervention, including endpoint/change means, variances, group-specific n, analysis model, P, and CI.
Conditions for verification: Link the directly eligible single-ingredient intervention's between-group difference in inflammatory-lesion change, endpoint difference, P, CI, and denominators to the exact analysis.
Requirement and applicability: Required
Application exceptions: Do not calculate new effects or intervals by reconstructing graphs or using baseline SDs or other lesion counts.
Why this condition is needed: Needed to avoid filling the gap in single-ingredient inflammatory-lesion effects with numbers for total lesions or combination products.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application — internal adaptation for the target between-group effect. This is not official methodological certification.

N20 · Was precision kept from being filled in using baseline SDs or significance for other endpoints?

Required materials and conditions: Variances of inflammatory-lesion change/endpoint values, group-specific n, and SE/CI appropriate to the analysis.
Conditions for verification: Distinguish the target effect's variance/SE/CI from baseline means (SDs) and P for other endpoints.
Requirement and applicability: Required
Application exceptions: Do not convert the existing empty axes.precision value into a score of 0, high precision, or a new interval.
Why this condition is needed: Because the presence of sample sizes or baseline SDs alone cannot establish the precision of the target effect.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M15 §15.3.1–15.3.3; internal application — internal adaptation for variances/intervals. This is not official methodological certification.

N21 · Were the outcomes and denominators to which P=0.0197 and 68.21% refer preserved?

Required materials and conditions: Original total-lesion results table, calculation formula/denominator for 68.21%, group/time point, and effect direction.
Conditions for verification: Attribute the total-lesion P and the 68.21% wording only to the original product/analysis, and indicate that the calculation formula and denominator are unverified.
Requirement and applicability: Required (preservation of related results)
Application exceptions: Do not accept 68.21% as an additional reduction relative to placebo or an effect of pantothenic acid alone.
Why this condition is needed: Needed to retain favorable adjacent results without repurposing them as single-ingredient inflammatory-lesion effects.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application — internal adaptation for favorable total-lesion values. This is not official methodological certification.

N22 · Can the contribution of B5 be separated from the combination product's effect?

Required materials and conditions: Full composition, ingredient-specific comparators or appropriate factorial comparisons, and common-background data.
Conditions for verification: Check whether there is a comparison in which other active ingredients and common treatments are held constant and only B5 differs.
Requirement and applicability: Required
Application exceptions: Do not delete the product results as invalid; retain them as adjacent results for the original product.
Why this condition is needed: Because a randomized product-level comparison does not automatically estimate a separately identified ingredient-level causal effect.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed — internal adaptation for separating ingredient contributions. This is not official methodological certification.

N23 · Was the 2012 change of 20.45→11.18 kept from being converted into a between-group effect?

Required materials and conditions: The 2012 results table, global-lesion definition, within-group analysis, flow of 11 enrolled/10 completed, and detailed composition.
Conditions for verification: Attribute within-group changes in global lesions from an uncontrolled, open-label study to their separate product/endpoint/denominator.
Requirement and applicability: Required (preservation of related results)
Application exceptions: Do not newly calculate placebo effects, additional effects, or reduction percentages from within-group changes.
Why this condition is needed: Needed to distinguish improvement over time from additional improvement relative to a comparator.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed; M08 §8.2.2, M15 §15.3.1; internal application — internal adaptation for uncontrolled within-group results. This is not official methodological certification.

N24 · Was Saki's P=0.476 kept from being used as an effect of 0 for oral single-ingredient supplementation?

Required materials and conditions: Saki's actual molecule/formulation, intramuscular administration, adapalene background, analysis groups/time points, and original results table.
Conditions for verification: Attribute the P for the endpoint-value comparison involving a different route, molecule, and background only to that analysis.
Requirement and applicability: Required (boundaries for contrary results)
Application exceptions: Preserve the dexpanthenol description in the original KO and the Pantothenic Acid wording in the paper title; do not resolve molecular identity from the names alone.
Why this condition is needed: Needed to retain the related nonsignificant result without mistaking it for repeated counterevidence against oral pantothenic acid.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed — internal adaptation for other routes/no detected difference. This is not official methodological certification.

N25 · Was the Leung bibliographic lead kept from being converted into an eligible RCT result?

Required materials and conditions: Leung's original text, actual study design/population, single-ingredient oral intervention, and between-group inflammatory-lesion results.
Conditions for verification: Distinguish indexing, hypotheses, and citations in other papers from actual controlled designs and verified results.
Requirement and applicability: Required (candidate boundaries)
Application exceptions: Do not interpret unacquired full text or an unverified design as a negative result or absence of research.
Why this condition is needed: Needed to avoid creating a single-ingredient RCT or a causal effect merely because a citation exists.
Referenced methods: The distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design; M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed — internal adaptation for historical hypotheses/bibliographic records. This is not official methodological certification.

N26 · Were S09–S11 kept from being repurposed as direct acne results?

Required materials and conditions: The original citations' populations, routes, and endpoints, and the scope of legacy carryover; original results if needed.
Conditions for verification: Distinguish material carried over from legacy 028, female hair loss, and topical dexpanthenol/hydration/barrier outcomes from the current question.
Requirement and applicability: Required (attribution of related material)
Application exceptions: The legacy 028 or reference files are not labeled as directly read in this review, and their clinical numerical values are not inherited.
Why this condition is needed: Needed to avoid combining different populations, routes, and measures merely because they share a vitamin name or concern skin.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; the distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed — internal adaptation for legacy/other endpoints. This is not official methodological certification.

N27 · Can the planned inflammatory endpoints/time points be compared with the reports?

Required materials and conditions: Official registration history, protocol, SAP, reasons for endpoint changes, and reported results.
Conditions for verification: Compare the target endpoints/time points/denominators in registrations, protocols, and SAP with actual reports, and explicitly state nonacquisition.
Requirement and applicability: Required
Application exceptions: Do not convert an empty nct value or gaps in registration access into nonregistration, confirmed selective reporting, or negative results. The S02 slide is not a protocol.
Why this condition is needed: Because material is needed to compare reporting of total lesions as primary and inflammatory lesions as secondary with advance plans and possible selective reporting.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design — internal adaptation for registration/analysis plans. This is not official methodological certification.

N28 · Were sponsorship, institutions, declarations, and unverified information distinguished?

Required materials and conditions: Research funding/publication fees, product provision, author employment/patents, COI, and sponsor roles in the research.
Conditions for verification: Record each report's funding, publication fees, affiliations, and COI declarations separately from unverified employment/product provision/patents.
Requirement and applicability: Supplementary; required for claims of independence
Application exceptions: Do not exclude results merely because sponsorship exists, and do not sustain a claim of independence using unverified information.
Why this condition is needed: Needed to avoid automatically accepting a declaration of no conflicts of interest or unverified funding as independent replication or absence of bias.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodology sections in this pilot do not endorse all of these detailed items — internal adaptation for funding/conflicts of interest. This is not official methodological certification.

N29 · Were differences among related studies kept from being counted as independent replications of single-active-ingredient treatment?

Required materials and conditions: Unique trial identity, eligibility/results tables, single-active-ingredient composition, each endpoint/time point, and information on independent institutions.
Conditions for verification: Distinguish direct replications that match the report family, single-active-ingredient status, population, route, lesion type, and time point from adjacent results.
Requirement and applicability: Required (interpretation of replication)
Application exceptions: Do not extend unverified direct eligibility to 0 studies worldwide or assign Not applicable to unverified study-family information.
Why this condition is needed: Needed to avoid turning results from the same brand, appendices, or other routes into reproduction or replicated refutation of efficacy for inflammatory lesions from a single active ingredient.
Referenced methods: Distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application — internal adaptation for direct replication and differences. This is not official methodological certification.

N30 · Is there evidence for judging the clinical importance of a difference in lesion counts?

Required materials and conditions: Between-group effects/CI for the target inflammatory lesions, evidence of importance from the patient's perspective, and prespecified criteria.
Conditions for verification: Link direct effects/intervals separately to criteria for a lesion difference that matters to patients.
Requirement and applicability: Required (interpretation of importance)
Application exceptions: Do not assign numerical values to MCID, a minimum lesion difference, sample size, or duration without supporting evidence.
Why this condition is needed: Needed to avoid declaring a clinically sufficient effect for the original question based only on significance for total lesions or study size.
Referenced methods: M15 §15.3.1–15.3.3; internal application — internal adaptation for clinical importance. This is not official methodological certification.

N31 · Were NAD/skin-hydration results kept from being used as effects on inflammatory lesions?

Required materials and conditions: Definition of the selected endpoint and the actual evidence and interpretive scope for each related mechanism/other clinical measure.
Conditions for verification: Distinguish the lesion count being treated from mechanisms, nutritional markers, topical barrier/hydration, and separate quality-of-life/event questions.
Requirement and applicability: Supplementary; required for expansion to other clinical questions
Application exceptions: Because the lesions themselves are the treatment target, do not impose clinical-event/mortality trials as mandatory for this lesion-count question.
Why this condition is needed: Needed to prevent mechanistic plausibility or skin relevance from substituting for the original question of oral single-active-ingredient efficacy.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed; M03 §3.2.4; internally defined extension boundaries — internal adaptation for mechanistic and clinical boundaries. This is not official methodological certification.

N32 · Are optimal dose, persistence after discontinuation, and subgroup effects imposed as mandatory?

Required materials and conditions: Direct dose comparisons, discontinuation/long-term follow-up, and prespecified subgroup and interaction data when making expanded claims.
Conditions for verification: Treat claims about optimization, persistence, and subgroups that are absent from the current narrow lesion-count question as separate questions.
Requirement and applicability: Supplementary; required only for the relevant expansion
Application exceptions: Unverified actual doses and assessment time points for the single-active-ingredient product remain under the separate required conditions N10/N11 and are not erased by this Not applicable status.
Why this condition is needed: Needed to avoid making every dose, long-term, and subgroup study outside the assessed question universally mandatory.
Referenced methods: M03 §3.2.1–3.2.4; details on dose, persistence, and effect modification are internally designed — internal adaptation for obligations for expanded questions. This is not official methodological certification.

N33 · Was the lack of reported serious adverse events in a short combination-product study kept from being turned into safety?

Required materials and conditions: Tables of adverse events by arm, event/person counts, collection methods, denominators/durations, and discontinuation/missing data for a single-active-ingredient product.
Conditions for verification: Distinguish harm collection, events/persons, exposure/denominators, discontinuation, and nonreporting by product/duration.
Requirement and applicability: Supplementary; required for safety interpretation
Application exceptions: Do not calculate unreported event counts, incidence, or discontinuations, or generate causal harm estimates.
Why this condition is needed: Needed to avoid generalizing nonreporting in a small combination-product study into 0 events during long-term single-active-ingredient use or safety certification.
Referenced methods: M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; detailed distinctions are internally designed; M19 §19.1.2–19.2.4, M04 §4.6.3; internal application — internal adaptation for adverse-event records. This is not official methodological certification.

N34 · Were the meanings of 5 mg/day, 10 g/day, and the absence of an established UL distinguished?

Required materials and conditions: Relevant sections of official nutrition/excess-intake risk documents and safety data for the actual formulation, population, and exposure.
Conditions for verification: Distinguish nutritional reference values, gastrointestinal harm examples, and the absence of an established upper intake level from therapeutic doses, toxicity thresholds, or safety guarantees.
Requirement and applicability: Supplementary; required for defining safety scope
Application exceptions: The official web document was not newly read in this review, and the original numbers are not converted into toxicity thresholds or efficacious doses.
Why this condition is needed: Needed to avoid mistaking official examples and an unestablished upper limit for an individual therapeutic dose or unlimited safety.
Referenced methods: M19 §19.1.2–19.2.4; internal application; Chamgap's own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed — internal adaptation for nutrition and risk examples. This is not official methodological certification.

N35 · Were safety gaps for high doses, special populations, and interactions retained?

Required materials and conditions: Data on long-term use/special populations, underlying diseases, concomitant medications, interactions, and discontinuation/recovery for single-active-ingredient formulations.
Conditions for verification: Distinguish short-term product observations from the scope of long-term single-active-ingredient use, pregnancy/lactation, children, liver/kidney disease, and concomitant medications.
Requirement and applicability: Supplementary; required for the relevant safety expansion
Application exceptions: Do not impose every rare-harm study on the narrow lesion-efficacy question, and do not newly assess individual causality, risk, or discontinuation/rechallenge.
Why this condition is needed: Needed to avoid generalizing limited product observations or a statement of no known interactions into safety for all populations.
Referenced methods: M19 §19.1.2–19.2.4; internal application; design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed — internal adaptation for long-term use and vulnerable groups. This is not official methodological certification.

N36 · Was the lack of direct verification kept from being extended to worldwide absence or a current search?

Required materials and conditions: Original search/selection ledger, registration/access records, correction/retraction information, and current original-text versions.
Conditions for verification: Specify the original reference date, search/access limitations at that time, the scope of the current preservation conversion, and links to individual updates.
Requirement and applicability: Required
Application exceptions: No searches, external full-text reading, or registration/API lookups were performed in this review. Failures described in the manuscript are not retroactively relabeled as events in this review.
Why this condition is needed: Needed to avoid guaranteeing an absence of studies in a current exhaustive search from a direct evidence gap within the recorded search scope.
Referenced methods: M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design; M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed — internal adaptation for search and update scope. This is not official methodological certification.

N37 · Were the scope of the original ?, empty values, axes, and direct-human-evidence flags preserved?

Required materials and conditions: The gate scope of the original grade/score, axes, and assessment_profile, together with self-review and publication metadata.
Conditions for verification: Preserve the original ?/empty score, B/P, unscored empty values, and flags restricted to direct eligibility without a new judgment.
Requirement and applicability: Required (preservation contract)
Application exceptions: Do not inherit C from an adjacent product or C from legacy 028, and do not use the original self-review or grade_revalidated as independent certification in this review.
Why this condition is needed: Needed to avoid turning unverified direct eligibility into absence of all human evidence, a score of 0, no effect, or new clinical certification.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design — internal adaptation for preservation of the original judgment. This is not official methodological certification.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly document the question, eligibility criteria, and reasons for changes, and distinguish intervention variants.
Extent of review: Reuse of previously preserved HTML and principles from 1585. This is not new reading of full methodology, application of an official tool, or certification in this review.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish and link studies and reports, and do not exclude a study solely because outcomes are unreported.
Extent of review: Reuse of previously preserved HTML and principles from 1585. This is not new reading of full methodology, application of an official tool, or certification in this review.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Fix the outcome and effect of interest, and review randomization, deviations, missing data, measurement, and selective reporting.
Extent of review: Reuse of previously preserved HTML and principles from 1585. This is not new reading of full methodology, application of an official tool, or certification in this review.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance, and applicability. Sample size alone does not determine precision.
Extent of review: Reuse of previously preserved HTML and principles from 1585. This is not new reading of full methodology, application of an official tool, or certification in this review.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require designs, populations, and follow-up different from those for efficacy. Case reports do not establish incidence.
Extent of review: Reuse of previously preserved HTML and principles from 1585. This is not new reading of full methodology, application of an official tool, or certification in this review.

What the statuses mean

Met: The original identity, values, and interpretive boundaries were verified in archived materials. This is separate from clinical sufficiency or certification.
Partly verified: Some material has been linked, but directness, detailed data, and comparison remain unresolved.
Unverified: The direct material/values needed within the preserved scope actually read are unverified. This does not mean no effect, 0 events, or incomplete review of the production work.
Not applicable: The obligation for expansion outside the narrow assessed question is not applicable. This is not a substitute for unread material.
Not applicable (alias): Display alias for Not applicable.
Not read: External original materials were not directly read in this review; this is separate from the current reading of summaries.
Conflicting information: Original disagreement within the same item; no arbitrary correction.
Review incomplete: Individual review of table production remains incomplete. This is distinguished from insufficient evidence.

Change history

2026-11-02 · Public page/material version 1.0

The public display and data were prepared from the existing 37 items. No new clinical search, verification-status change, or scoring was performed.

The stored-material review date (2026-10-05) and original evidence cut-off (2026-09-15) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which single question is linked to the original verdict URL?

Current findings: The current /ko/effect is a reduction in inflammatory lesion counts in adults with mild-to-moderate facial acne. subclaims is an empty array, and the related 028 is linked as a historical mixed claim. This table covers the original main question alone.
Verification status: Met
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The current claim, subclaim structure, and original verdict identity were linked to the actual preserved archived summaries. This is separate from verification of efficacy.
Reason for missing information: The eligible single-active-ingredient formulation, dose, duration, and between-group numerical results remain unverified under subsequent conditions.
Required materials and conditions: The current assessment target, facets, empty subclaims, canonical URL, and identity of the related 028.
Materials to obtain first: The current assessment target, facets, empty subclaims, canonical URL, and identity of the related 028.
Further research: Before incorporating new material, use an inclusion/exclusion table to compare the assessment target with the population, intervention, and endpoint of each result.
Remaining uncertainty: The existence of other skin outcomes cannot replace the current question about inflammatory lesions.
Conditions for verification: Link the original /ko/effect to adult facial acne, oral pantothenic acid as the sole active ingredient, inflammatory lesion counts, and a placebo comparison with the same background treatment.
Why this condition is needed: Required to avoid merging other skin effects or the existing mixed claim 028 into the efficacy of the single ingredient assessed here.
Application exceptions: Korean/English versions and adjacent outcomes such as total lesions do not automatically generate separate independent claims.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed — internal adaptation for a separate claim. This is not official methodological certification.

Related sources S01 S03 S04

N02 · Was the effect of pantothenic acid alone distinguished from the product effect?

Current findings: The question concerns oral pantothenic acid as the sole active ingredient. The current manuscript could not verify that the 2014 Pantothen product had a sole active ingredient, and keeps calcium pantothenate in a separate verification stratum. Topical, intramuscular, and NAD mechanism material is not used as evidence of the effect of oral monotherapy.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The question boundaries are clear, but the actual identity of the directly eligible single-active-ingredient intervention has not been verified.
Reason for missing information: The exact chemical form and complete active composition of the single-active-ingredient formulation are unverified.
Required materials and conditions: Material documenting all active ingredients, the exact salt, actual route, product, and batch of the single-active-ingredient formulation.
Materials to obtain first: Material documenting all active ingredients, the exact salt, actual route, product, and batch of the single-active-ingredient formulation.
Further research: Code each trial's intervention in a table of ingredients, salts, routes, and concurrent ingredients, and first assess direct comparability.
Remaining uncertainty: The words pantothenic acid in a title or a brand name do not guarantee sole-active-ingredient status or equivalence of a batch.
Conditions for verification: Verify whether the exact active ingredient, molecule, and route match the fixed question, and separate results from combination products.
Why this condition is needed: The presence of an ingredient alone cannot establish its isolated effect.
Application exceptions: Calcium pantothenate and the free acid are not automatically treated as equivalent; dexpanthenol and topical/intramuscular material are kept within the boundaries of adjacent evidence.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed — internal adaptation for a sole active ingredient. This is not official methodological certification.

Related sources S01 S03 S04 S06 S10 S11

N03 · Was summary reading in this review distinguished from historical access to original texts?

Current findings: The currently preserved KO/EN text, evidence, and bibliography were actually read. The historical full_text for S01/S04/S06, the full-document PDF for S02, full_text_mirror for S03, metadata_search_index for S05, and inherited_local_record for S09–S11 are preserved unchanged. Access to all external original texts was not attempted, and none were acquired or read in this review.
Verification status: Met
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: Current summary reading and the historical access level of each material were recorded separately. This does not mean that external full-text verification is complete.
Reason for missing information: Actual access dates for individual citations and current external bytes are unavailable. The historical source ledger and old 028 files were also not read in this review.
Required materials and conditions: The preserved URL, location, and access_level for each citation, and any records of individual access dates/acquired copies, if available.
Materials to obtain first: The preserved URL, location, and access_level for each citation, and any records of individual access dates/acquired copies, if available.
Further research: For each actual acquisition event, record document type, bytes, verification location, and access/reading times separately, and compare them with the summary reader.
Remaining uncertainty: The original global review date 2026-09-15 is not converted into individual access dates or successful external access on 2026-10-05.
Conditions for verification: Separate the currently archived summaries actually read, each report's historical access_level, external access not attempted/material not read in this review, and the absence of access dates.
Why this condition is needed: Required to avoid mistaking an external link or historical full_text for full-text reading in this review.
Application exceptions: Because the original citation has no access date, leave the value empty and record the global verified_date separately as the material review date.
Referenced methods: Material collection/selection principles in M04 §4.5–4.6; separation of access and reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design — internal adaptation for the level of reading. This is not official methodological certification.

Related sources S01 S02 S03 S04 S05 S06 S09 S10 S11

N04 · Were the Yang main text and supplementary slide kept from being double-counted as trials?

Current findings: The S01 main text and S02 single-page summary slide belong to the same Yang 2014 material set. The original evidence labels them S01 F01, S03 F02, S04 F03, and S05 F04. These labels are not newly added up as unique eligible trials, independent replications, or a participant total.
Verification status: Partly verified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The linkage between the same paper and its appendix is verified, but the independent identities and duplication of all studies have not been exhaustively verified.
Reason for missing information: Detailed original family/selection ledgers and cross-checks of all registrations and batches remain outstanding.
Required materials and conditions: Each report's DOI, year, trial identity, supplementary-material linkage, and original evidence family_id.
Materials to obtain first: Each report's DOI, year, trial identity, supplementary-material linkage, and original evidence family_id.
Further research: Group related reports in a trial-identity table and compare titles, DOI, duration, populations, and batches to identify duplication and unestablished matters.
Remaining uncertainty: The count of 9 reports does not mean 9 clinical trials or 9 independent replications.
Conditions for verification: Link S01/S02 to the same 2014 Yang family, and distinguish the original F01–F04 labels from a count of independent trials.
Why this condition is needed: Required to avoid adding a paper and its appendix as independent replications or assuming that materials from different years of the same brand concern an identical batch.
Application exceptions: S03 is the original F02 uncontrolled material from 2012. Even with the same Pantothen brand, batch identity with S01 is unverified.
Referenced methods: Distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application — internal adaptation for report and trial families. This is not official methodological certification.

Related sources S01 S02 S03 S04 S05

N05 · Does the material directly match adults with mild-to-moderate facial acne?

Current findings: The original target population is adults with mild-to-moderate facial acne. Yang/Capodice are related facial-acne studies, but sole-active-ingredient product status and actual population details have not been established as currently directly eligible evidence.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The current facets define the target population for the question, but information on selection and representativeness of an eligible single-active-ingredient population is unverified.
Reason for missing information: Actual diagnostic criteria, age groups, severity, and exclusion criteria for the single-active-ingredient trial remain outstanding.
Required materials and conditions: Tables of diagnosis, age/severity distributions, inclusion/exclusion, and baseline treatment in single-active-ingredient trials.
Materials to obtain first: Tables of diagnosis, age/severity distributions, inclusion/exclusion, and baseline treatment in single-active-ingredient trials.
Further research: Prepare an eligibility table by diagnosis, severity, and baseline treatment to review differences between the original target population and study populations.
Remaining uncertainty: The inclusion of adults in the question is not generalized into effects in children, other body areas, or severe acne.
Conditions for verification: Compare diagnosis, age, severity, lesion location, inclusion/exclusion, and the actual directly eligible population.
Why this condition is needed: The label facial acne alone does not establish that populations and clinical selection are the same.
Application exceptions: The phrase mild-to-moderate facial acne in the title of an adjacent study is not extended into verification of all actual population details.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed — internal adaptation for population and selection. This is not official methodological certification.

Related sources S01 S03

N06 · Was the hypothesis of deficiency correction distinguished from efficacy for acne in general?

Current findings: The original facets explicitly distinguish this from efficacy in correcting deficiency. Leung 1995 is a bibliographic lead for a deficiency hypothesis and related reports; directly eligible between-group results for inflammatory lesions are unverified.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The deficiency boundary was preserved, but the actual population's baseline status or effects by deficiency status have not been verified.
Reason for missing information: Baseline deficiency identification, proportions, and stratum-specific comparative results are unavailable.
Required materials and conditions: Baseline nutritional status, methods of identifying deficiency, and direct comparative results within that stratum.
Materials to obtain first: Baseline nutritional status, methods of identifying deficiency, and direct comparative results within that stratum.
Further research: Separate deficient and nondeficient strata only in studies with baseline-status data, and compare whether effect modification was prespecified.
Remaining uncertainty: This table does not newly establish the hypothesis that deficiency causes acne or that supplementation is necessary.
Conditions for verification: Distinguish baseline pantothenic acid status, deficiency diagnosis, and correction outcomes from a comparison of monotherapy for acne.
Why this condition is needed: Required to avoid transferring a deficiency hypothesis to efficacy in an unverified general acne population.
Application exceptions: Unverified baseline status is not filled in as normal or deficient. The S05 hypothesis is not a single-active-ingredient RCT with results.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed; question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed — internal adaptation for the deficiency boundary. This is not official methodological certification.

Related sources S05

N07 · Were the salt, formulation, and manufacturing batch of the eligible single-active-ingredient product verified?

Current findings: The manufacturing source, exact salt, brand, purity, batch, release formulation, and medication adherence for the current single-active-ingredient product are unverified. Calcium pantothenate was retained as a separate search stratum, and equal effects with the free acid were not assumed.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The formulation identity left unverified in the manuscript cannot be filled in as actual manufacturing certification.
Reason for missing information: Actual chemical-form and quality/batch data for the directly eligible single-active-ingredient product are needed.
Required materials and conditions: Trial-batch manufacturing/composition certificates, complete label, salt and labeled-amount basis, and formulation-quality data.
Materials to obtain first: Trial-batch manufacturing/composition certificates, complete label, salt and labeled-amount basis, and formulation-quality data.
Further research: Separate the salt, active-amount basis, excipients, and purity in batch records, and compare the trial intervention with the label for agreement.
Remaining uncertainty: Molecular names or routes in other papers are not corrected on the basis of terminology alone or merged as the same product.
Conditions for verification: Link the exact salt, manufacturing source, purity, batch, release formulation, and tablet/capsule to the actual trial product.
Why this condition is needed: Product names and labeled amounts alone cannot establish the actual sole active ingredient or exposure.
Application exceptions: The efficacy and doses of the calcium salt and free acid are not converted as equivalent. The presence of excipients alone does not establish that a product has multiple active ingredients.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed — internal adaptation for salt, batch, and quality. This is not official methodological certification.

Related sources S01 S03 S06

N08 · Can the sole-active-ingredient status of the 2014 Pantothen product be verified?

Current findings: Yang 2014 is a 12-week study of Pantothen. There is a report that 4 tablets contain pantothenic acid 2.2 g, but the complete active composition, exact salt, and trial-batch certificate are currently unverified. An identical batch to the same brand's 2012 composition was not assumed.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The amount of pantothenic acid contained and verification that it is the sole active ingredient are different conditions, and the latter is not met.
Reason for missing information: The complete composition and evidence of sole-active-ingredient status for the relevant year and trial batch remain outstanding.
Required materials and conditions: The complete active composition, exact salt, and batch certificate for the 2014 batch, and comparator ingredients.
Materials to obtain first: The complete active composition, exact salt, and batch certificate for the 2014 batch, and comparator ingredients.
Further research: Compare the 2014 batch composition with a placebo under the same background treatment, and review whether a comparison isolates the single ingredient.
Remaining uncertainty: The single-page summary slide in S02 does not substitute for a composition certificate or protocol.
Conditions for verification: Verify all active ingredients in the relevant 2014 trial batch and assess whether its effect can be separately attributed to B5.
Why this condition is needed: Required to avoid accepting the product effect in a related RCT as the effect of the selected ingredient alone.
Application exceptions: The fact that the 2012 product had multiple ingredients does not establish that the 2014 batch was identical.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application — internal adaptation for 2014 product composition. This is not official methodological certification.

Related sources S01 S02 S03

N09 · Were the other ingredients and dosing of the 2012 product distinguished?

Current findings: The 2012 Pantothen product is described as having multiple ingredients, including other vitamins and L-carnitine. The dosing was 2 tablets per administration, 2 times daily for 8 weeks, and the manuscript reports that the complete composition extraction and unverified units were left in a separate ledger. That ledger was not read in this review.
Verification status: Partly verified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The preserved description of multiple ingredients, frequency, and duration was linked, but complete ingredient amounts and units were not verified.
Reason for missing information: The exact amount and unit of each active ingredient and the complete batch composition are unverified.
Required materials and conditions: The complete active composition, amounts/units of each ingredient, dosing records, and product-batch data for 2012.
Materials to obtain first: The complete active composition, amounts/units of each ingredient, dosing records, and product-batch data for 2012.
Further research: Reconstruct a table of actual amounts and dosing frequency by ingredient, leave unverified composition empty, and assess the possibility of an isolated comparison.
Remaining uncertainty: Material from a different year for the same brand is not counted as the identical intervention or an independent monotherapy replication.
Conditions for verification: Attribute the multiple ingredients, L-carnitine, and dosing frequency in 2012 and the 8-week observation to that product alone.
Why this condition is needed: Required to avoid repurposing within-group results for a combination product as comparative efficacy of pantothenic acid alone.
Application exceptions: Complete composition or unit extractions absent from the current archived summaries are not supplemented from old ledgers or the brand name.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application — internal adaptation for the 2012 combination product. This is not official methodological certification.

Related sources S03

N10 · Was the reported dose kept from being converted into a therapeutic dose for the single-active-ingredient product?

Current findings: The reported amount for the 2014 product is 2.2 g/day, described as the content of 4 tablets. The manuscript does not use this as a verified therapeutic dose of B5 alone. The directly eligible monotherapy dose and actual adherence are unverified.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: A reported product amount is available, but verified actual exposure to a single-active-ingredient product matching the question is unavailable.
Reason for missing information: Actual active amounts, medication adherence, and other intake for the single-active-ingredient product are needed.
Required materials and conditions: Labeled-amount basis, frequency, actual use/adherence, diet, and other supplemental intake for the eligible single-active-ingredient product.
Materials to obtain first: Labeled-amount basis, frequency, actual use/adherence, diet, and other supplemental intake for the eligible single-active-ingredient product.
Further research: After reviewing adherence while separating labeled amounts from actual exposure, assess whether there are direct dose comparisons of the same formulation.
Remaining uncertainty: The adult nutritional reference of 5 mg/day and the NIH example of 10 g/day are not a basis for establishing a clinical dose.
Conditions for verification: Distinguish the product's reported amount from the actual active amount, adherence, and total intake for the single-active-ingredient product.
Why this condition is needed: Required to avoid presenting the adjacent product's 2.2 g/day as a verified dose for acne treatment with the single ingredient alone.
Application exceptions: Salt conversions, actual intake, and optimal doses absent from the original material are not calculated.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.1–3.2.4; details on dose, duration, and effect modification are internally designed — internal adaptation for labeled and actual amounts. This is not official methodological certification.

Related sources S01 S03 S06

N11 · Were product observation periods distinguished from eligible single-active-ingredient time points?

Current findings: Yang 2014 is preserved as 12 weeks, Capodice 2012 as 8 weeks, and Saki 2025's separate intramuscular comparison as 2 months. The duration and assessment time point of directly eligible monotherapy are unverified in facets.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The adjacent durations were read, but they cannot replace the single-active-ingredient time point in the original question.
Reason for missing information: Actual dosing duration, assessment time points, and continued follow-up for the eligible single-active-ingredient product are unavailable.
Required materials and conditions: Start/end dates, assessment schedules, duration of observation, and endpoint-specific timelines for the single-active-ingredient product.
Materials to obtain first: Start/end dates, assessment schedules, duration of observation, and endpoint-specific timelines for the single-active-ingredient product.
Further research: Separate dosing, assessment, and analysis time points by report in a timeline, and review comparability of the same endpoint at the same time point.
Remaining uncertainty: Differences in duration alone are not grounds for classification as conflicting information or no effect.
Conditions for verification: Attribute 12 weeks, 8 weeks, and 2 months to their respective reports, and keep treatment/assessment time points for the eligible single-active-ingredient product separate.
Why this condition is needed: Required to avoid combining adjacent comparisons of different durations into a direct effect at a single time point.
Application exceptions: S04's 2 months are not newly converted to 8 weeks, and nominal duration is not assumed to establish actual exposure or complete follow-up.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.1–3.2.4; details on dose, duration, and effect modification are internally designed — internal adaptation for duration and time points. This is not official methodological certification.

Related sources S01 S03 S04

N12 · Was the difference between the single-active-ingredient product and placebo under the same background treatment verified?

Current findings: The original comparator is placebo under the same background treatment, but the detailed composition of the actual single-active-ingredient comparison is unverified. Yang is a related placebo-controlled product trial, while Saki's adapalene background is a comparison involving a different route.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The design label placebo-controlled alone cannot verify sole-active-ingredient status or matching background conditions.
Reason for missing information: The complete placebo ingredients and group-specific concomitant/rescue treatment, adherence, and deviation data remain outstanding.
Required materials and conditions: Complete composition of the single-active-ingredient product/placebo, common treatment by group, rescue treatment/changes, and adherence records.
Materials to obtain first: Complete composition of the single-active-ingredient product/placebo, common treatment by group, rescue treatment/changes, and adherence records.
Further research: Design a comparison of the single-active-ingredient product and a matching placebo under the same background treatment, and prespecify recording and analysis of changes in concomitant/rescue treatment.
Remaining uncertainty: Even if background treatment for another route is verified, this does not establish the effect of oral monotherapy.
Conditions for verification: Separate placebo composition, concomitant/rescue treatment, adherence, and deviations from the difference in the sole active ingredient.
Why this condition is needed: Required to avoid attributing contributions from concurrent ingredients or other treatments to pantothenic acid alone.
Application exceptions: Compare the effect of interest and actual management in each group rather than requiring complete identity of all changes in both groups.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptation for tests are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application — internal adaptation for placebo and background treatment. This is not official methodological certification.

Related sources S01 S04

N13 · Were the actual allocation process and baseline balance verified?

Current findings: Yang's original design is a randomized, double-blind, placebo-controlled study lasting 12 weeks, and Capodice is an uncontrolled, open-label study lasting 8 weeks. The archived summaries read in this review contain no review of sequence generation, allocation concealment, or baseline balance for a directly eligible single-active-ingredient product.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: Design labels from related product trials were not upgraded into verification of methods for a single-active-ingredient comparison.
Reason for missing information: Allocation procedures, concealment, and baseline balance for the direct single-active-ingredient comparison are needed.
Required materials and conditions: Random sequence, concealment, group-specific baseline tables, and original methods text for the direct single-active-ingredient comparison.
Materials to obtain first: Random sequence, concealment, group-specific baseline tables, and original methods text for the direct single-active-ingredient comparison.
Further research: Compare the methods and baseline tables against outcome-specific allocation/concealment questions, and separate unverified elements.
Remaining uncertainty: This table is not an official RoB 2 assessment or a definitive bias judgment.
Conditions for verification: Compare the allocation method, concealment, and baseline balance for the selected result separately from the study label.
Why this condition is needed: The labels randomized and double-blind alone cannot establish that all allocation and confounding problems were resolved.
Application exceptions: Preserve the uncontrolled S03 material as well, and do not automatically assign Not applicable for crossover/cluster design when the direct design is unverified.
Referenced methods: M08 §8.1–8.2.3; internal application — internal adaptation for allocation and concealment. This is not official methodological certification.

Related sources S01 S03

N14 · Were 15.3(8.9) and 17.3(14.3) kept from being used as effects?

Current findings: The retained text reports the baseline inflammatory-lesion mean (SD) in Table 1 as 15.3(8.9) for the product group and 17.3(14.3) for the placebo group. This is a baseline comparison, not a treatment effect, endpoint value, or CI.
Verification status: Met
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The original attribution to baseline, group, and mean/SD was preserved, and no new effect was calculated.
Reason for missing information: Inflammatory-lesion endpoint/change values and their variances, denominators, and intervals remain separately unverified.
Required materials and conditions: The baseline table's means/SDs, groups/time points, and denominators, and the endpoint/change results table for the outcome concerned.
Materials to obtain first: The baseline table's means/SDs, groups/time points, and denominators, and the endpoint/change results table for the outcome concerned.
Further research: Cross-check each numerical value in the table by group, time point, and statistic, and extract baseline values separately from treatment results.
Remaining uncertainty: The external Table 1 was not reread in this review; the values were transferred from the retained text.
Conditions for verification: Distinguish the baseline inflammatory-lesion means and SDs in Table 1 from endpoint values, differences in change, SE, and CI.
Why this condition is needed: Needed to avoid converting baseline lesion counts or parenthesized SDs into single-ingredient effects and precision values.
Application exceptions: Do not newly calculate endpoint differences, differences in change, or CI from baseline SDs and sample sizes.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.1–8.2.3; internal application — internal adaptation for baseline means/SDs. This is not official methodological certification.

Related sources S01

N15 · Were inflammatory lesions separated from total lesions and other assessments?

Current findings: Yang's primary endpoint is total lesions, while inflammatory lesions and other endpoints are reported as secondary. The original question concerns the between-group difference in change in inflammatory-lesion counts; the endpoint difference is separate. Total-lesion results were not used as inflammatory-lesion results.
Verification status: Partly verified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The difference in endpoints was verified, but the precise lesion classifications, measurement methods, and target results table remain to be verified.
Reason for missing information: Detailed comparison of inflammatory/noninflammatory counting definitions, other scales, and endpoint-specific results/hierarchy is unverified.
Required materials and conditions: Lesion classifications, counting definitions, the primary/secondary endpoint table, and between-group results for each endpoint.
Materials to obtain first: Lesion classifications, counting definitions, the primary/secondary endpoint table, and between-group results for each endpoint.
Further research: Specify inflammatory lesions as the prespecified endpoint of interest and report total lesions, noninflammatory lesions, and other scales as separate results.
Remaining uncertainty: Additional scales such as IGA were not verified from the currently retained archived summaries, and significance for total lesions is not repurposed.
Conditions for verification: Separate the definitions/priorities of inflammatory-lesion counts, total lesions, noninflammatory lesions, and other clinical assessments.
Why this condition is needed: Needed to avoid automatically substituting total-lesion results for the original inflammatory-lesion effect.
Application exceptions: Do not fill in values or priorities for other scales, such as IGA, that are absent from the currently archived summaries.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application — internal adaptation for endpoint types. This is not official methodological certification.

Related sources S01

N16 · Can the actual procedures for lesion counting and assessor blinding be determined?

Current findings: The retained original assessment records that the lesions themselves are the treatment target and are not reclassified as surrogate markers merely because they are counted by an observer. Yang's design is described as double-blind, but details of lesion-counting procedures and assessor blinding are currently unverified.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: Endpoint classification and the design designation alone cannot substitute for verification of the actual measurement process.
Reason for missing information: The assessor's counting method, training/agreement, maintenance of blinding, and collection at identical time points are needed.
Required materials and conditions: Lesion-counting manual, assessor training/agreement, maintenance of blinding, and collection schedules by group.
Materials to obtain first: Lesion-counting manual, assessor training/agreement, maintenance of blinding, and collection schedules by group.
Further research: Review blinded assessment and agreement in advance using standardized counting procedures, and record differences in measurement schedules between groups.
Remaining uncertainty: Insufficient measurement-procedure information does not mean an effect of 0 or confirmed measurement bias.
Conditions for verification: Verify inflammatory-lesion assessors, counting rules, assessment time points, blinding, and measurement differences between groups.
Why this condition is needed: Needed to avoid judging a measurement to be objective or a surrogate endpoint merely because it is called an observer count.
Application exceptions: Do not repurpose the double-blind designation as verification of actual lesion-assessor blinding or measurement limitations.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; internal application — internal adaptation for counting/blinding. This is not official methodological certification.

Related sources S01

N17 · Which analyses do 48/41 and the group-specific 20/21 counts belong to?

Current findings: S01 reports 48 allocated and 41 evaluated, with group-specific counts of 20/21. The original what_research explicitly states that the endpoint-specific analysis denominator for inflammatory lesions could not be verified. No group assignment for 20/21 or ITT denominator was added from this n field alone.
Verification status: Partly verified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The original allocation/evaluation counts were preserved, but endpoint-specific denominators, group correspondence, and analysis definitions remain to be verified.
Reason for missing information: The actual group-specific analysis n for inflammatory lesions and correspondence to each flow stage/group are unverified.
Required materials and conditions: Flow diagram, group-specific allocation/completion/analysis table, endpoint-specific analysis n, and group identification.
Materials to obtain first: Flow diagram, group-specific allocation/completion/analysis table, endpoint-specific analysis n, and group identification.
Further research: Separate the flow table into allocation, completion, and target-endpoint analysis, and compare denominator links by group/time point.
Remaining uncertainty: Do not calculate a new dropout rate, effect, or event rate from 48 and 41.
Conditions for verification: Distinguish allocation, evaluation, and group-specific reported counts from the inflammatory-lesion analysis denominator, and do not infer group correspondence.
Why this condition is needed: Needed to avoid immediately converting an evaluable sample into the target endpoint's ITT denominator or group-specific participants.
Application exceptions: Do not newly map the group-specific 20/21 order in the current n field to product/placebo without the original material.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application — internal adaptation for allocation/evaluation denominators. This is not official methodological certification.

Related sources S01

N18 · Were people who were not evaluated and the handling of ITT/PP verified?

Current findings: S01's 48 allocated and 41 evaluated and S03's 11 enrolled and 10 completed are different data. The currently archived summaries did not verify group-specific reasons for missing inflammatory-lesion data or ITT/PP, imputation, and sensitivity handling.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: Only flow counts are available, without evidence on missing-data/analysis handling for the target outcome.
Reason for missing information: Group-specific reasons for attrition, missing inflammatory-endpoint data, analysis populations, and handling principles are needed.
Required materials and conditions: Reasons for loss to follow-up/discontinuation by group, ITT/PP definitions, missing-data handling, and sensitivity analyses.
Materials to obtain first: Reasons for loss to follow-up/discontinuation by group, ITT/PP definitions, missing-data handling, and sensitivity analyses.
Further research: Distinguish interest in the effect of assignment from the effect of adherence, and compare analysis plans/sensitivity analyses that include missing endpoint data.
Remaining uncertainty: Do not convert unverified information into 0 dropouts or confirmed selection bias.
Conditions for verification: Link reasons for missing data/discontinuation, their distribution by group, analysis populations, and imputation/sensitivity handling to the target endpoint.
Why this condition is needed: Needed to avoid transferring selected evaluable results to an effect among everyone allocated.
Application exceptions: Do not arbitrarily assign ITT or PP if the original text does not specify the analysis.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application — internal adaptation for missing data/analysis populations. This is not official methodological certification.

Related sources S01 S03

N19 · Are the between-group difference, P, and CI for inflammatory lesions with the single-ingredient intervention available?

Current findings: The current primary_effect records for mean_difference, confidence_interval, p_value, and analysis sample size are all empty. The manuscript records that an eligible controlled result for the single-ingredient intervention and exact inflammatory-lesion endpoint values, between-group differences in change, CI, P, and endpoint-specific n could not be verified.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The empty values for the original target effect and analysis data were preserved as they were, without filling them with adjacent values.
Reason for missing information: Effect estimates, uncertainty, denominators, and analysis definitions for the target single-ingredient outcome are needed.
Required materials and conditions: Results table for the directly relevant single-ingredient intervention, including endpoint/change means, variances, group-specific n, analysis model, P, and CI.
Materials to obtain first: Results table for the directly relevant single-ingredient intervention, including endpoint/change means, variances, group-specific n, analysis model, P, and CI.
Further research: In a single-ingredient intervention–placebo comparison with the same background treatment, report between-group estimates and intervals for the prespecified inflammatory endpoint by analysis population.
Remaining uncertainty: Empty values do not mean an effect of 0, nonsignificance, or equivalence.
Conditions for verification: Link the directly eligible single-ingredient intervention's between-group difference in inflammatory-lesion change, endpoint difference, P, CI, and denominators to the exact analysis.
Why this condition is needed: Needed to avoid filling the gap in single-ingredient inflammatory-lesion effects with numbers for total lesions or combination products.
Application exceptions: Do not calculate new effects or intervals by reconstructing graphs or using baseline SDs or other lesion counts.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application — internal adaptation for the target between-group effect. This is not official methodological certification.

Related sources S01 S02 S03

N20 · Was precision kept from being filled in using baseline SDs or significance for other endpoints?

Current findings: The Table 1 values 15.3(8.9) and 17.3(14.3) are baseline means (SDs). The direct-effect CI and SE are empty in the current calculation record, and the precision axis also retains its original empty value. No new interval was constructed from these values.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: Baseline variance and target-effect precision are separate, and the required direct interval is absent.
Reason for missing information: Endpoint-specific change/endpoint variances, SE, CI, and analysis denominators remain to be verified.
Required materials and conditions: Variances of inflammatory-lesion change/endpoint values, group-specific n, and SE/CI appropriate to the analysis.
Materials to obtain first: Variances of inflammatory-lesion change/endpoint values, group-specific n, and SE/CI appropriate to the analysis.
Further research: Compare change-score variances and intervals appropriate to the original analysis, and record limitations imposed by missing-data assumptions on interval interpretation.
Remaining uncertainty: The total-lesion P=0.0197 does not signify adequate precision for the inflammatory-lesion result of the single-ingredient intervention.
Conditions for verification: Distinguish the target effect's variance/SE/CI from baseline means (SDs) and P for other endpoints.
Why this condition is needed: Because the presence of sample sizes or baseline SDs alone cannot establish the precision of the target effect.
Application exceptions: Do not convert the existing empty axes.precision value into a score of 0, high precision, or a new interval.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M15 §15.3.1–15.3.3; internal application — internal adaptation for variances/intervals. This is not official methodological certification.

Related sources S01

N21 · Were the outcomes and denominators to which P=0.0197 and 68.21% refer preserved?

Current findings: Yang's total-lesion result P=0.0197 and the 68.21% wording were retained as originally reported. The formula and denominator for 68.21% are unclear, so it was not accepted as an additional reduction relative to placebo, and the total-lesion P was not assigned to inflammatory lesions.
Verification status: Partly verified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The presence and limitations of the favorable values were verified, but their formula, denominator, and direct attribution remain to be verified.
Reason for missing information: The exact formula, comparison reference, and denominator for 68.21%, and the original endpoint-specific tables, are needed.
Required materials and conditions: Original total-lesion results table, calculation formula/denominator for 68.21%, group/time point, and effect direction.
Materials to obtain first: Original total-lesion results table, calculation formula/denominator for 68.21%, group/time point, and effect direction.
Further research: Compare the wording's formula, denominator, group, and endpoint with the original table, and verify from the original definition whether it represents an additional effect relative to placebo.
Remaining uncertainty: Do not newly calculate relative/absolute reduction percentages or the single ingredient's contribution.
Conditions for verification: Attribute the total-lesion P and the 68.21% wording only to the original product/analysis, and indicate that the calculation formula and denominator are unverified.
Why this condition is needed: Needed to retain favorable adjacent results without repurposing them as single-ingredient inflammatory-lesion effects.
Application exceptions: Do not accept 68.21% as an additional reduction relative to placebo or an effect of pantothenic acid alone.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application — internal adaptation for favorable total-lesion values. This is not official methodological certification.

Related sources S01

N22 · Can the contribution of B5 be separated from the combination product's effect?

Current findings: The current manuscript distinguishes the effects of pantothenic acid alone from those of products containing pantothenic acid. The sole-active-ingredient status of the 2014 product is unverified, and the 2012 product has multiple ingredients. The separate contribution of B5 could not be verified from the results for both products.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: Product comparisons and within-group changes are available, but there are no data separating the contribution of the sole active ingredient.
Reason for missing information: A direct comparison in which only B5 differs, full active-ingredient composition, and identical background conditions are needed.
Required materials and conditions: Full composition, ingredient-specific comparators or appropriate factorial comparisons, and common-background data.
Materials to obtain first: Full composition, ingredient-specific comparators or appropriate factorial comparisons, and common-background data.
Further research: Review a single-ingredient comparison in which only B5 differs, or a factorial design with ingredient contributions defined in advance.
Remaining uncertainty: Do not interpret unverified composition as counterevidence showing that B5 has no effect.
Conditions for verification: Check whether there is a comparison in which other active ingredients and common treatments are held constant and only B5 differs.
Why this condition is needed: Because a randomized product-level comparison does not automatically estimate a separately identified ingredient-level causal effect.
Application exceptions: Do not delete the product results as invalid; retain them as adjacent results for the original product.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed — internal adaptation for separating ingredient contributions. This is not official methodological certification.

Related sources S01 S03

N23 · Was the 2012 change of 20.45→11.18 kept from being converted into a between-group effect?

Current findings: Capodice 2012 is an uncontrolled, open-label study over 8 weeks, with 11 enrolled and 10 completed as reported. The global-lesion change of 20.45→11.18 is a within-group change with a multi-ingredient product, not an inflammatory-lesion effect relative to placebo.
Verification status: Partly verified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The original favorable within-group result was preserved, but the comparator, sole-active-ingredient status, and target endpoint differ from the original question.
Reason for missing information: A direct controlled comparison of the single-ingredient intervention and results for the target inflammatory-lesion outcome were not acquired.
Required materials and conditions: The 2012 results table, global-lesion definition, within-group analysis, flow of 11 enrolled/10 completed, and detailed composition.
Materials to obtain first: The 2012 results table, global-lesion definition, within-group analysis, flow of 11 enrolled/10 completed, and detailed composition.
Further research: Extract within-group results separately, and compare alternative explanations involving temporal change, regression, and concurrent treatment against comparative data.
Remaining uncertainty: Do not convert the limitation of no comparator into absence of results or invalidity of the study itself.
Conditions for verification: Attribute within-group changes in global lesions from an uncontrolled, open-label study to their separate product/endpoint/denominator.
Why this condition is needed: Needed to distinguish improvement over time from additional improvement relative to a comparator.
Application exceptions: Do not newly calculate placebo effects, additional effects, or reduction percentages from within-group changes.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed; M08 §8.2.2, M15 §15.3.1; internal application — internal adaptation for uncontrolled within-group results. This is not official methodological certification.

Related sources S03

N24 · Was Saki's P=0.476 kept from being used as an effect of 0 for oral single-ingredient supplementation?

Current findings: Saki 2025 is described in the original KO as a study adding intramuscular dexpanthenol to topical adapalene, while the original paper title says Pantothenic Acid. The single-blind design, 2 months, analysis groups of 31/28, and between-group P=0.476 for inflammatory-lesion endpoint values are preserved. This is a nonsignificant result for a different route/molecule and is not used as an oral B5 effect of 0 or repeated counterevidence.
Verification status: Partly verified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The separate result and exclusion boundaries were linked, but the external formulation/molecule, denominators, and original table were not newly verified.
Reason for missing information: Actual formulation identity, group correspondence, endpoint variances/intervals, and detailed material on that background remain to be verified.
Required materials and conditions: Saki's actual molecule/formulation, intramuscular administration, adapalene background, analysis groups/time points, and original results table.
Materials to obtain first: Saki's actual molecule/formulation, intramuscular administration, adapalene background, analysis groups/time points, and original results table.
Further research: Compare differences in the reported title, actual administered formulation, route, background, and endpoint timing to distinguish the basis for judging directness.
Remaining uncertainty: Nonsignificance is not an effect of 0 or equivalence, and the title and administered-molecule wording are not arbitrarily corrected.
Conditions for verification: Attribute the P for the endpoint-value comparison involving a different route, molecule, and background only to that analysis.
Why this condition is needed: Needed to retain the related nonsignificant result without mistaking it for repeated counterevidence against oral pantothenic acid.
Application exceptions: Preserve the dexpanthenol description in the original KO and the Pantothenic Acid wording in the paper title; do not resolve molecular identity from the names alone.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed — internal adaptation for other routes/no detected difference. This is not official methodological certification.

Related sources S04

N25 · Was the Leung bibliographic lead kept from being converted into an eligible RCT result?

Current findings: Leung 1995 is classified in the original evidence as a historical hypothesis/related report; the directly relevant controlled design, n, and between-group inflammatory-lesion results in the original text are unverified. Historical access is recorded as metadata_search_index, and the publisher's full text is recorded as not having been obtained.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: A bibliographic identity is available, but no material links it to an eligible comparative result.
Reason for missing information: The original text, comparative design, actual intervention, and between-group inflammatory-lesion analysis are needed.
Required materials and conditions: Leung's original text, actual study design/population, single-ingredient oral intervention, and between-group inflammatory-lesion results.
Materials to obtain first: Leung's original text, actual study design/population, single-ingredient oral intervention, and between-group inflammatory-lesion results.
Further research: If the original text is acquired, separate hypotheses from observational/trial results and compare them with the current question using an eligibility table.
Remaining uncertainty: The historical failure to acquire material recorded in the manuscript does not mean a new access failure in this review.
Conditions for verification: Distinguish indexing, hypotheses, and citations in other papers from actual controlled designs and verified results.
Why this condition is needed: Needed to avoid creating a single-ingredient RCT or a causal effect merely because a citation exists.
Application exceptions: Do not interpret unacquired full text or an unverified design as a negative result or absence of research.
Referenced methods: The distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design; M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed — internal adaptation for historical hypotheses/bibliographic records. This is not official methodological certification.

Related sources S05

N26 · Were S09–S11 kept from being repurposed as direct acne results?

Current findings: S09 is a comparison involving calcium pantothenate and other treatments for female hair loss, S10 is a review of topical dexpanthenol, and S11 is a bibliographic record for a topical barrier/hydration study. The original citation specifies that only sources and boundaries were carried over from the previous 028 and that these are not numerical clinical evidence for this review. The current external originals and legacy 028 were not read.
Verification status: Met
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The current citations verified the scope of carryover and the boundary that these concern different questions. The efficacy of those studies was not newly verified.
Reason for missing information: Full original texts and comparison of these materials' specific populations/results are outside this review's scope and are not filled in as current numerical values.
Required materials and conditions: The original citations' populations, routes, and endpoints, and the scope of legacy carryover; original results if needed.
Materials to obtain first: The original citations' populations, routes, and endpoints, and the scope of legacy carryover; original results if needed.
Further research: Separate each carried-over citation into a population, molecule, route, and endpoint table to distinguish discovery context from direct results.
Remaining uncertainty: Hair-loss and topical hydration/barrier results are not results for inflammatory lesions in acne treated with oral single-ingredient supplementation.
Conditions for verification: Distinguish material carried over from legacy 028, female hair loss, and topical dexpanthenol/hydration/barrier outcomes from the current question.
Why this condition is needed: Needed to avoid combining different populations, routes, and measures merely because they share a vitamin name or concern skin.
Application exceptions: The legacy 028 or reference files are not labeled as directly read in this review, and their clinical numerical values are not inherited.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; the distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed — internal adaptation for legacy/other endpoints. This is not official methodological certification.

Related sources S09 S10 S11

N27 · Can the planned inflammatory endpoints/time points be compared with the reports?

Current findings: The original limitations explicitly state that registration/analysis plans are unverified, and the nct values in evidence are empty. The original search summary reports some registration/API access failures. S02 is a single summary slide, not a composition certificate or protocol. No registration/API lookup was performed in this review.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: No material permits direct comparison of advance plans with actual endpoints/denominators.
Reason for missing information: Official registration content/history, protocols, SAP, and reasons for changes are needed.
Required materials and conditions: Official registration history, protocol, SAP, reasons for endpoint changes, and reported results.
Materials to obtain first: Official registration history, protocol, SAP, reasons for endpoint changes, and reported results.
Further research: Compare initial registration/change histories, protocols, and SAP with report endpoints, time points, and analyses step by step.
Remaining uncertainty: The detailed access-failure log was not read in this review, so no new failure event or nonregistration is established.
Conditions for verification: Compare the target endpoints/time points/denominators in registrations, protocols, and SAP with actual reports, and explicitly state nonacquisition.
Why this condition is needed: Because material is needed to compare reporting of total lesions as primary and inflammatory lesions as secondary with advance plans and possible selective reporting.
Application exceptions: Do not convert an empty nct value or gaps in registration access into nonregistration, confirmed selective reporting, or negative results. The S02 slide is not a protocol.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design — internal adaptation for registration/analysis plans. This is not official methodological certification.

Related sources S01 S02 S03 S04

N28 · Were sponsorship, institutions, declarations, and unverified information distinguished?

Current findings: S01 reports Avilan research funding, Nutraceutical Medical Research publication fees, and a declaration of no conflicts of interest. S03 is affiliated with Nutraceutical Medical Research, while details of funding, product provision, employment/patents, and COI are unverified. S04 is retained with Shiraz University, Actoverco, and a declaration of no conflicts of interest; S05 is retained with funding unverified.
Verification status: Partly verified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The reported funding/declarations were verified, but not all employment, patents, or sponsor roles were verified.
Reason for missing information: Details for S03/S05 and each sponsor's roles in design, analysis, and publication remain unresolved.
Required materials and conditions: Research funding/publication fees, product provision, author employment/patents, COI, and sponsor roles in the research.
Materials to obtain first: Research funding/publication fees, product provision, author employment/patents, COI, and sponsor roles in the research.
Further research: Compare funding sources, institutions, employment, patents, and sponsor roles by report in a table, and preserve results regardless of their direction.
Remaining uncertainty: Funding or COI declarations alone are not used to make a new judgment about independence or the reliability of the results.
Conditions for verification: Record each report's funding, publication fees, affiliations, and COI declarations separately from unverified employment/product provision/patents.
Why this condition is needed: Needed to avoid automatically accepting a declaration of no conflicts of interest or unverified funding as independent replication or absence of bias.
Application exceptions: Do not exclude results merely because sponsorship exists, and do not sustain a claim of independence using unverified information.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodology sections in this pilot do not endorse all of these detailed items — internal adaptation for funding/conflicts of interest. This is not official methodological certification.

Related sources S01 S03 S04 S05

N29 · Were differences among related studies kept from being counted as independent replications of single-active-ingredient treatment?

Current findings: The original assessment limits its statement to not having verified a directly eligible controlled trial of a single active ingredient for the fixed endpoint, and records the existence of related human studies as true. Positive combination-product results, uncontrolled within-group results, nonsignificant results from another route, and hypothesis candidates were not added together as direct replications of single-active-ingredient treatment.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: Eligible single-active-ingredient results and independence information needed for a direct replication comparison are unavailable.
Reason for missing information: Effects, conditions, independence, and overlap linkages for each directly eligible study family are needed.
Required materials and conditions: Unique trial identity, eligibility/results tables, single-active-ingredient composition, each endpoint/time point, and information on independent institutions.
Materials to obtain first: Unique trial identity, eligibility/results tables, single-active-ingredient composition, each endpoint/time point, and information on independent institutions.
Further research: First compare eligibility and outcome differences by trial, then review direct independent replication separately after deduplication.
Remaining uncertainty: Empty replication/independence values do not prove 0 replications or agreement in the same direction.
Conditions for verification: Distinguish direct replications that match the report family, single-active-ingredient status, population, route, lesion type, and time point from adjacent results.
Why this condition is needed: Needed to avoid turning results from the same brand, appendices, or other routes into reproduction or replicated refutation of efficacy for inflammatory lesions from a single active ingredient.
Application exceptions: Do not extend unverified direct eligibility to 0 studies worldwide or assign Not applicable to unverified study-family information.
Referenced methods: Distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application — internal adaptation for direct replication and differences. This is not official methodological certification.

Related sources S01 S02 S03 S04 S05

N30 · Is there evidence for judging the clinical importance of a difference in lesion counts?

Current findings: The original assessment limitations leave MCID unverified, and direct effects/CI are also empty. Total-lesion P=0.0197 and 68.21% were not used as criteria for the clinical sufficiency of single-active-ingredient inflammatory-lesion results.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: Both the direct effect and the important-difference criterion are unverified, so sufficiency cannot be interpreted.
Reason for missing information: A direct interval for inflammatory lesions and an evidence-based criterion for an important difference are needed.
Required materials and conditions: Between-group effects/CI for the target inflammatory lesions, evidence of importance from the patient's perspective, and prespecified criteria.
Materials to obtain first: Between-group effects/CI for the target inflammatory lesions, evidence of importance from the patient's perspective, and prespecified criteria.
Further research: Review criteria linking patient experience to lesion differences, then present their relationship to the original intervals within a prespecified interpretation framework.
Remaining uncertainty: Do not turn the current judgment ? into a new conclusion of a clinically small effect or no effect.
Conditions for verification: Link direct effects/intervals separately to criteria for a lesion difference that matters to patients.
Why this condition is needed: Needed to avoid declaring a clinically sufficient effect for the original question based only on significance for total lesions or study size.
Application exceptions: Do not assign numerical values to MCID, a minimum lesion difference, sample size, or duration without supporting evidence.
Referenced methods: M15 §15.3.1–15.3.3; internal application — internal adaptation for clinical importance. This is not official methodological certification.

Related sources S01

N31 · Were NAD/skin-hydration results kept from being used as effects on inflammatory lesions?

Current findings: The original classification is a P endpoint in which inflammatory lesions themselves are the treatment target. The presence of pantothenic acid, NAD/cellular mechanisms, or topical moisturization does not demonstrate reduction of inflammatory lesions with an oral single active ingredient, and is not extended to effects on quality of life, scarring, or other events.
Verification status: Met
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The original P classification was linked to the boundary against substitution by related measures. No new efficacy judgment for events was created.
Reason for missing information: The complete original texts on mechanisms/topical outcomes were not read in this review, and the direct effect for the selected question remains unverified.
Required materials and conditions: Definition of the selected endpoint and the actual evidence and interpretive scope for each related mechanism/other clinical measure.
Materials to obtain first: Definition of the selected endpoint and the actual evidence and interpretive scope for each related mechanism/other clinical measure.
Further research: Record mechanistic explanations and clinical lesion comparisons as separate lines of evidence, and handle new questions such as quality of life or scarring through a separate boundary review.
Remaining uncertainty: A P classification does not mean efficacy is verified, and it is not changed to S on the basis that lesions are counted by an observer.
Conditions for verification: Distinguish the lesion count being treated from mechanisms, nutritional markers, topical barrier/hydration, and separate quality-of-life/event questions.
Why this condition is needed: Needed to prevent mechanistic plausibility or skin relevance from substituting for the original question of oral single-active-ingredient efficacy.
Application exceptions: Because the lesions themselves are the treatment target, do not impose clinical-event/mortality trials as mandatory for this lesion-count question.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed; M03 §3.2.4; internally defined extension boundaries — internal adaptation for mechanistic and clinical boundaries. This is not official methodological certification.

Related sources S01 S10 S11

N32 · Are optimal dose, persistence after discontinuation, and subgroup effects imposed as mandatory?

Current findings: The original /ko/effect is the single question of reducing inflammatory lesion counts in adults with mild-to-moderate facial acne; it makes no claim about optimal dose, persistence after discontinuation, or efficacy in specific subgroups. Only a blanket obligation to conduct these expanded studies is not applicable.
Verification status: Not applicable
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The obligation for expansion outside the narrow assessed question was treated as not applicable. Unverified actual single-active-ingredient dose, duration, and population remain unchanged.
Reason for missing information: Expanded outcomes were not verified; a new expanded question would require separate evidence.
Required materials and conditions: Direct dose comparisons, discontinuation/long-term follow-up, and prespecified subgroup and interaction data when making expanded claims.
Materials to obtain first: Direct dose comparisons, discontinuation/long-term follow-up, and prespecified subgroup and interaction data when making expanded claims.
Further research: If an expanded question is raised, separately design direct dose comparisons, follow-up after discontinuation, or a prespecified effect-modification plan.
Remaining uncertainty: Do not substitute Not applicable for unread material or unverified efficacy.
Conditions for verification: Treat claims about optimization, persistence, and subgroups that are absent from the current narrow lesion-count question as separate questions.
Why this condition is needed: Needed to avoid making every dose, long-term, and subgroup study outside the assessed question universally mandatory.
Application exceptions: Unverified actual doses and assessment time points for the single-active-ingredient product remain under the separate required conditions N10/N11 and are not erased by this Not applicable status.
Referenced methods: M03 §3.2.1–3.2.4; details on dose, persistence, and effect modification are internally designed — internal adaptation for obligations for expanded questions. This is not official methodological certification.

Related sources S01 S03

N33 · Was the lack of reported serious adverse events in a short combination-product study kept from being turned into safety?

Current findings: The original caution wording states that the lack of reported serious adverse events in the small 12-week combination-product trial was not generalized to long-term safety of a single-active-ingredient product. The current archived summaries contain no table of adverse events by arm, collection methods, denominators, or discontinuations for a directly relevant single-active-ingredient product.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The safety boundary is preserved, but quantitative harm and completeness-of-collection data for a directly relevant single-active-ingredient product are unverified.
Reason for missing information: Arm-specific counts of people with harm/events, exposure duration, collection methods, discontinuation, and the scope of nonreporting are needed.
Required materials and conditions: Tables of adverse events by arm, event/person counts, collection methods, denominators/durations, and discontinuation/missing data for a single-active-ingredient product.
Materials to obtain first: Tables of adverse events by arm, event/person counts, collection methods, denominators/durations, and discontinuation/missing data for a single-active-ingredient product.
Further research: Plan systematic harm collection and follow-up of discontinuations in the same formulation, population, and duration, and report persons/events and denominators separately.
Remaining uncertainty: Nonreporting differs from 0 events, safety, or absence of a cause. The 41 evaluable people for the product as a whole are not transferred to the harm-analysis denominator.
Conditions for verification: Distinguish harm collection, events/persons, exposure/denominators, discontinuation, and nonreporting by product/duration.
Why this condition is needed: Needed to avoid generalizing nonreporting in a small combination-product study into 0 events during long-term single-active-ingredient use or safety certification.
Application exceptions: Do not calculate unreported event counts, incidence, or discontinuations, or generate causal harm estimates.
Referenced methods: M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; detailed distinctions are internally designed; M19 §19.1.2–19.2.4, M04 §4.6.3; internal application — internal adaptation for adverse-event records. This is not official methodological certification.

Related sources S01 S03 S06

N34 · Were the meanings of 5 mg/day, 10 g/day, and the absence of an established UL distinguished?

Current findings: The preserved safety wording describes the adult adequate intake of 5 mg/day as a nutritional reference value and NIH's 10 g/day as an example associated with diarrhea/gastrointestinal discomfort. The 10 g/day value is not a toxicity threshold or intake recommendation, and the absence of an established UL does not mean unlimited safety.
Verification status: Met
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The original numbers and interpretive limitations were carried over. This is not new safety certification or personal dosing instructions.
Reason for missing information: Safety estimates and quantitative harm data for directly relevant single-active-ingredient high-dose use for acne remain separately unverified.
Required materials and conditions: Relevant sections of official nutrition/excess-intake risk documents and safety data for the actual formulation, population, and exposure.
Materials to obtain first: Relevant sections of official nutrition/excess-intake risk documents and safety data for the actual formulation, population, and exposure.
Further research: Compare the nature of official reference values and examples of harm-associated exposure by formulation, population, and duration, keeping them separate from personal recommendations.
Remaining uncertainty: The presence of an official web URL or the original access_level does not mean that updates to the material were verified in this review.
Conditions for verification: Distinguish nutritional reference values, gastrointestinal harm examples, and the absence of an established upper intake level from therapeutic doses, toxicity thresholds, or safety guarantees.
Why this condition is needed: Needed to avoid mistaking official examples and an unestablished upper limit for an individual therapeutic dose or unlimited safety.
Application exceptions: The official web document was not newly read in this review, and the original numbers are not converted into toxicity thresholds or efficacious doses.
Referenced methods: M19 §19.1.2–19.2.4; internal application; Chamgap's own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed — internal adaptation for nutrition and risk examples. This is not official methodological certification.

Related sources S06

N35 · Were safety gaps for high doses, special populations, and interactions retained?

Current findings: The manuscript explicitly states that the safety of high-dose use for acne in pregnancy, lactation, children, and liver/kidney disease is unverified. The statement that no important drug interactions are known does not exclude all interactions. Short combination-product data were not extended to long-term single-active-ingredient use.
Verification status: Unverified
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The original gaps are retained because direct verification of expanded safety data is absent.
Reason for missing information: Direct data by duration, underlying disease, vulnerable group, and concomitant medication remain needed.
Required materials and conditions: Data on long-term use/special populations, underlying diseases, concomitant medications, interactions, and discontinuation/recovery for single-active-ingredient formulations.
Materials to obtain first: Data on long-term use/special populations, underlying diseases, concomitant medications, interactions, and discontinuation/recovery for single-active-ingredient formulations.
Further research: Review designs for harm follow-up that distinguish populations, durations, and concomitant exposures, and report information gaps for vulnerable groups separately.
Remaining uncertainty: Lack of interaction information does not mean 0 interactions or individual safety.
Conditions for verification: Distinguish short-term product observations from the scope of long-term single-active-ingredient use, pregnancy/lactation, children, liver/kidney disease, and concomitant medications.
Why this condition is needed: Needed to avoid generalizing limited product observations or a statement of no known interactions into safety for all populations.
Application exceptions: Do not impose every rare-harm study on the narrow lesion-efficacy question, and do not newly assess individual causality, risk, or discontinuation/rechallenge.
Referenced methods: M19 §19.1.2–19.2.4; internal application; design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed — internal adaptation for long-term use and vulnerable groups. This is not official methodological certification.

Related sources S01 S06

N36 · Was the lack of direct verification kept from being extended to worldwide absence or a current search?

Current findings: The original reference date is 2026-09-15, and the judgment is limited to targeted search-engine searches, citation tracking, and accessible original texts. Some PubMed and registration/API failures and unacquired full texts are disclosed. The conversion in this review on 2026-10-05 involves reading archived materials, with no new search. New single-active-ingredient trials, composition information, target outcomes/SAP, corrections, or safety information are reasons for updates under the same ID/URL.
Verification status: Met
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The scope verified at that time was distinguished from and linked to the current work and specific reasons for updates.
Reason for missing information: Worldwide completeness, absence of unpublished studies, and the latest retraction/correction status were not verified in this review.
Required materials and conditions: Original search/selection ledger, registration/access records, correction/retraction information, and current original-text versions.
Materials to obtain first: Original search/selection ledger, registration/access records, correction/retraction information, and current original-text versions.
Further research: If new material becomes available within an authorized scope, distinguish search/access events, additions of evidence, and revisions of conditions, and re-review the linked rows.
Remaining uncertainty: This is a gap within the accessible scope; it does not declare 0 eligible studies worldwide.
Conditions for verification: Specify the original reference date, search/access limitations at that time, the scope of the current preservation conversion, and links to individual updates.
Why this condition is needed: Needed to avoid guaranteeing an absence of studies in a current exhaustive search from a direct evidence gap within the recorded search scope.
Application exceptions: No searches, external full-text reading, or registration/API lookups were performed in this review. Failures described in the manuscript are not retroactively relabeled as events in this review.
Referenced methods: M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design; M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed — internal adaptation for search and update scope. This is not official methodological certification.

Related sources S01 S02 S03 S04 S05 S06

N37 · Were the scope of the original ?, empty values, axes, and direct-human-evidence flags preserved?

Current findings: The original grade is ?, score is empty, and the 7 axes are B/P/the remaining five empty values. no_human_study=true and human_study_exists=false refer to directly eligible controlled trials of a single active ingredient for the fixed endpoint, while the existence of related human studies is true. The numerical and denominator fields of primary_effect are empty, and the original safety is Caution. Historical first_published_at and ready metadata do not mean publication on the website was completed in this review.
Verification status: Met
Materials actually read: Summary reading: the currently archived summaries were actually read; external original texts, registrations, and old separate files were not read.
Why unverified: The original values and scope were linked unchanged, without creating new scores, grades, effects, or publication certification.
Reason for missing information: Unscored axes, direct between-group results, and full-text/registration gaps remain unchanged.
Required materials and conditions: The gate scope of the original grade/score, axes, and assessment_profile, together with self-review and publication metadata.
Materials to obtain first: The gate scope of the original grade/score, axes, and assessment_profile, together with self-review and publication metadata.
Further research: Compare the preserved original text and display values, and treat only data/table-conversion errors as separate correction events.
Remaining uncertainty: The original single-assistant self-review and document quality B are neither independent clinical review nor a new efficacy grade B.
Conditions for verification: Preserve the original ?/empty score, B/P, unscored empty values, and flags restricted to direct eligibility without a new judgment.
Why this condition is needed: Needed to avoid turning unverified direct eligibility into absence of all human evidence, a score of 0, no effect, or new clinical certification.
Application exceptions: Do not inherit C from an adjacent product or C from legacy 028, and do not use the original self-review or grade_revalidated as independent certification in this review.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limitations on the current material conversion reflect the user's scope and internal design — internal adaptation for preservation of the original judgment. This is not official methodological certification.

Related sources S01 S03 S04 S05